

Curriculum vitae

Date Prepared: May 21, 2019

Name: James A. de Lemos

Office Address: 5323 Harry Hines Blvd, Room E5.728
Dallas, TX 75390-8830

Work Phone: **214-645-7500**

Work E-Mail: James.delemos@utsouthwestern.edu

Work Fax: 214-645-2480

Place of Birth: Riverside, CA

Education

Year	Degree (Honors)	Field of Study	Institution
1987	B.A. (Summa Cum Laude)	Liberal Arts	The University of Texas at Austin
1992	M.D.	Medicine	Harvard Medical School
1997	Certificate	Clinical Effectiveness Program	Harvard School of Public Health

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline	Institution
1992-1995	Intern/Resident	Internal Medicine	UT Southwestern Medical Center, Dallas, TX
1995-1996	Chief Resident	Internal Medicine	UT Southwestern Medical Center, Dallas, TX
1996-1999	Fellow	Cardiology	The Brigham and Women's Hospital, Boston, MA

Current Licensure and Certification

Licensure

1993 Texas (J4073)

Board and Other Certification

1995 American Board of Internal Medicine Certification

1999, 2009 Cardiovascular Subspecialty Certification

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
1982	National Merit Scholar	
1987	Phi Beta Kappa	The University of Texas at Austin
1987	Graduated <i>summa cum laude</i> with special honors	The University of Texas at Austin
1998	Eugene Braunwald Fellow	Brigham and Women's Hospital
1998	Soma Weiss Award for excellence in teaching by a fellow	Brigham and Women's Hospital
2002-2004	Career Development Award	Glaxo-Smith-Kline
2005	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2005	Outstanding Teacher Award	Internal Medicine Training Program
2006	Elite Reviewer	<i>Journal of the American College of Cardiology</i>
2007	Elite Reviewer	<i>Journal of the American College of Cardiology</i>
2008	Elite Reviewer	<i>Journal of the American College of Cardiology</i>
2009	Elite Reviewer	<i>Journal of the American College of Cardiology</i>
2010	Super Doctors, Cardiology	<i>Texas Monthly</i>
2010	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2011	Core Clerkship Teaching Award	UT Southwestern Medical School
2011	Super Doctors, Cardiology	<i>Texas Monthly</i>
2011	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2012	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2012	Super Doctors, Cardiology	<i>Texas Monthly</i>
2012	Simon Dack Award	<i>Journal of the American College of Cardiology</i>
2012	Parmley Prize for best paper by young faculty; Mentor for awardee Sandeep Das	<i>Journal of the American College of Cardiology</i>
2013	Super Doctors, Cardiology	<i>Texas Monthly</i>
2014	Super Doctors, Cardiology	<i>Texas Monthly</i>
2014	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>

2014	Elected Member	<i>American Society of Clinical Investigation</i>
2015	Women in Cardiology Mentorship Award	American Heart Association
2015	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2015	Distinguished Educator Award Nominee	UT Southwestern Medical School
2015	Highlighted Cited Researcher (Top 1% by citations for field and publication year in Web of Science)	Thomson Reuters
2016	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2016	Super Doctors, Cardiology	<i>Texas Monthly</i>
2016	Highlighted Cited Researcher (Top 1% by citations for field and publication year in Web of Science)	Clarivate
2017	Elected Member	<i>Association of American Physicians</i>
2017	Faculty Mentorship Award	<i>Internal Medicine Training Program</i>
2017	L. David Hillis Teaching Award	<i>Cardiology Fellowship Training Program</i>
2017	Best Doctors in Dallas, Cardiology	<i>D Magazine</i>
2017	Highly Cited Researcher (Top 1% by citations for field and publication year in Web of Science)	Clarivate
2018	Highly Cited Researcher (Top 1% by citations for field and publication year in Web of Science)	Clarivate
2018	University of Texas Board of Regents Outstanding Teacher Award	UT System Board of Regents

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
1995-1996	Assistant Instructor	Internal Medicine	UT Southwestern
1996-1999	Clinical Fellow	Internal Medicine	Harvard Medical School
1999-2000	Instructor	Internal Medicine	Harvard Medical School
2000-2005	Assistant Professor	Internal Medicine	UT Southwestern

2005-2009	J. Fred Schoellkopf, Jr. Chair in Cardiology Research	Internal Medicine	UT Southwestern
2005-2011	Associate Professor	Internal Medicine	UT Southwestern
2009-present	Sweetheart BallKern Wildenthal, MD, PhD Distinguished Chair in Cardiology	Internal Medicine	UT Southwestern
2011-2018	Professor	Internal Medicine	UT Southwestern Medical Center
2018-	Professor with Tenure	Internal Medicine	UT Southwestern Medical Center
2018-	Distinguished Teaching Professor	UT Board of Regents	UT Southwestern/UT System

Appointments at Hospitals/Affiliated Institutions

<u>Past</u>			
Year(s)	Position Title	Department/Division	Institution
1995-1996	Attending Physician	Medicine	Parkland Memorial Hospital
1995-1996	Attending Physician	Medicine	Dallas VA Medical Center
1996-1999	Clinical Fellow	Medicine/Cardiology	Brigham and Women's Hospital
1999-2000	Associate Physician	Medicine/Cardiology	Brigham and Women's Hospital
2000-2005	Attending Physician	Medicine/Cardiology	Dallas VA Medical Center
<u>Current</u>			
Year(s)	Position Title	Department/Division	Institution
2000-present	Attending Physician	Medicine/Cardiology	Zale-Lipshy University Hospital
2000-present	Attending Physician	Medicine/Cardiology	Parkland Memorial Hospital
2002-present	Attending Physician	Medicine/Cardiology	St. Paul/Clements University Hospital

Other Professional Positions

None

Major Administrative/Leadership Positions

Year(s)	Position Title	Institution
1995-1996	Chief Medical Resident	UT Southwestern
2000-2002	Director, Outpatient Clinics	Parkland Memorial Hospital
2001-2015	Director, Coronary Care Unit	Parkland Memorial Hospital

2002-2011	Director MSIV Critical Care Rotation in Cardiology	UT Southwestern
2005-2011	Director, Cardiovascular Fellowship Training Program	UT Southwestern
2011-2015	Cardiology Service Chief	Parkland Memorial Hospital
2007-present	Medical Director, Dallas Heart Study	UT Southwestern
2009-present	Co-Director T32 Training Grant	UT Southwestern
2011-2016	Associate Director, Cardiovascular Fellowship Training Program	UT Southwestern
2011-2012	Key Function PI for CTSA grant renewal application	UT Southwestern
2013-2017	Key Function PI for CTSA Grant	UT Southwestern
2017-2019	Associate Director, CTSA grant renewal application	UT Southwestern

Committee Service (*Member, unless noted otherwise*)

Year(s)	Name of Committee	Institution/Organization
<u>UTSW</u>		
1995-1996	Committee to Evaluate Clinical Competence, Internal Medicine Residency	UT Southwestern
1995-1996	Ambulatory Care Education Planning Committee, Internal Medicine Residency	UT Southwestern
1995-1996	Curriculum Committee, Internal Medicine Residency Training Program	UT Southwestern
1999	St. Paul Cardiology Clinic Design Committee	UT Southwestern
2000-present	Interviewer, IM Residency Applicants	UT Southwestern
2000-present	Curriculum Committee, Internal Medicine Residency Training Program	UT Southwestern
2001-2002	Task Force to Evaluate Research in Clinical Departments	UT Southwestern
2005-present	Executive Council, Cardiovascular Division	UT Southwestern
2005-2008	Committee to Evaluate Clinical Competence, Internal Medicine Training Program	UT Southwestern
2008- present	T32 Training Grant Executive Committee	UT Southwestern
2009	Co-chair, Clinical Research Excellence Task Force	UT Southwestern
2009	Clinical Science Education Subcommittee	UT Southwestern
2009-2010	Chair, Research Committee, New University Hospital Design	UT Southwestern

2012-2013	Chair, Search Committee, Director of Interventional Cardiology	UT Southwestern
2013-2014	Search Committee, Founding Chair of Department of Emergency Medicine	UT Southwestern
2014-2016	Search Committee, Nephrology Division Chief	UT Southwestern
2014-present	Internal Medicine Department Promotion and Tenure Review Committee	UT Southwestern
2015-2016	Search Committee GI Division Chief	UT Southwestern
2017-present	Selection Committee SWHR Clinical Scholars Program	UT Southwestern
<u>Hospital</u>		
1993-1996	Parkland Center for Internal Medicine Planning Committee	Parkland Memorial Hospital
1995-1996	Medicine Performance Improvement Committee	Parkland Memorial Hospital
1995-1996	Quality Assurance Reviewer	Parkland Memorial Hospital
1995-1996	ICU Committee	Parkland Memorial Hospital
1995-1996	Committee to Reorganize Medicine/Psychiatry Emergency Care	Parkland Memorial Hospital
1995-1996	Medical Records Committee	Dallas VA Medical Center
1995-1996	Laboratory Utilization Review Committee	Dallas VA Medical Center
1995-1996	Emergency Services Committee	Parkland Memorial Hospital
1998-2000	Clinical Services Committee, Cardiology Division	Brigham and Women's Hospital, Harvard Medical School
1998-2000	Interviewer, Fellowship Selection Committee	Brigham and Women's Hospital,
2000-2003	Medicine Performance Improvement Committee	Parkland Memorial Hospital
2002-present	Pharmacy P & T Cardiology Subcommittee	Parkland Memorial Hospital
2002-present	Pharmacy P & T Anticoagulation Subcommittee	Parkland Memorial Hospital
2006-2008	Resuscitation Committee	Parkland Memorial Hospital
2006-2012	Critical Care Committee	Parkland Memorial Hospital
2009-2015	Chair, Cardiovascular High Performance Committee	Parkland Memorial Hospital
<u>State/Regional</u>		
None		
<u>National/International</u>		
2000-2003	Operations and Steering Committee, FASTER trial	TIMI Study Group

2001-2004	Lead Investigator and Executive Committee, A to Z Trial	TIMI Study Group and Duke Clinical Research Institute
2004	Steering Committee, USE BNP Trial	Siemens Diagnostics
2004-2007	Steering Committee, MERLIN Trial,	TIMI Study Group
2004-present	Steering Committee, ImPROVE IT Trial	TIMI Research Group and Duke Clinical Research Institute
2005-2009	Steering Committee, AVANT-GARDE TIMI 43	TIMI Research Group
2006	NHLBI workshop on CRP	NHLBI
2007-2008	Data Safety and Monitoring Board, APPRAISE-1 trial	Duke Clinical Research Institute
2007-2011	Clinical Events Committee, VA Coronary Revascularization in Diabetes Study	VA Clinical Trials Program
2008-2009	Clinical Event Committee, PLATO trial	Duke Clinical Research Institute
2009	Committee on Qualification of Biomarkers as Surrogate Endpoints in Chronic Disease Risk. Ad-hoc participant	Institute of Medicine
2009-2011	Data Safety and Monitoring Board, APPRAISE-2 trial	Duke Clinical Research Institute
2010-2011	US Operations Committee, ECLIPSE Trial	Duke Clinical Research Institute
2010-2011	Data Safety and Monitoring Board, ELEVATE/TIMI 56 Trial	TIMI Study Group
2010-2012	Clinical Events Committee, Welcol Program	Daiichi-Sankyo
2011-2013	Clinical Event Committee, RECORD trial	Duke Clinical Research Institute
2011-2016	Data Safety and Monitoring Board, REFINE/ICD Trial	University of Calgary
2012-2015	Data Safety and Monitoring Board, Analyze ST Trial	St. Jude
2013-2018	US FDA Cardiorenal Advisory Panel	Food and Drug Administration
2013-present	Chair, Data Safety and Monitoring Board, DEVOTE Trial NN1250-4080 (Comparison of insulin degludec versus insulin glargine)	Novo Nordisc
2013-2015	Data Safety and Monitoring Committee, LATTITUDE-TIMI 60 Trial	TIMI Study Group
2014-present	Sarnoff Cardiovascular Research Foundation Scientific Committee	Sarnoff Foundation
2015-present	Steering Committee, GOULD Registry	Amgen
2016-present	Executive Editor <i>Circulation</i>	Am Heart Association
2016-present	DSMB Chair DEFINE-HF trial	Mid America Heart Institute
2016-2018	Executive Council	Association of University Cardiologists

2017-present	Evinacumab Data Monitoring Committee	Regeneron
2017-present	DSMB Chair PRESERVED-HF trial	Mid America Heart Institute
2017-present	DSMB Chair EBRACE-HF trial	Mid America Heart Institute
2017-present	Chair, Data Monitoring Committee, SOUL Trial	Novo Nordisc
2017-present	DSMB Member: R01 HL134893, PI Jennifer Ho, Association of Metabolic Disease and Pulmonary Hypertension	NIH/NHLBI
2018-present	DSMB Chair REAL-TIMI 63B	TIMI Study Group
2018-present	US FDA Endocrine and Metabolic Panel	Food and Drug Administration

Professional Societies

Dates	Society Name, member
1990-1994	American Medical Association
1990-2001	Massachusetts Medical Society
1992-present	Texas Medical Association
1992-present	Dallas County Medical Society
1993-1996	American College of Physicians
1996-present	American College of Cardiology (Fellow)
2000-present	Abstract Reviewer (2000-present)
2006, 13, 15	Peer Reviewer, ACC/AHA Guidelines (STEMI, UA/NSTEMI, DAPT)
2007-present	ACTION <input type="checkbox"/> (Acute Coronary Treatment and Interventions Outcomes Network)
2007-2010	Member, Research and Publications Committee
2010-2016	Steering Committee
2010-2016	Chair, Research and Publications Committee
2007-2012	ACC Foundation Research Awards Review and Selection Committee
2010-2012	ACC/AHA STEMI Practice Guideline Writing Committee
2011-2013	Scientific Sessions Program Committee, Co-coordinator Acute Coronary Syndromes
2013-2014	Scientific Sessions Program Committee, Coordinator Acute Coronary Syndromes
2014	ACC/AHA STEMI Practice Guideline Update Committee

1998-present	American Heart Association (Fellow)
2000-present	Abstract Reviewer 2000-present
2002-2004	Young Clinician-Investigator Committee
2004-2007	Acute Cardiac Care Committee
2005-2014	Participant, Scientific Sessions Planning Committee (2005-2006, 2009-2014)
2006-2009	Expert Panel on Subclinical Atherosclerotic Disease and Emerging Risk Factors
2010	Peer Reviewer, STEMI/NSTEMI Performance Measures Statement
2010-2012	AHA/ACC STEMI Practice Guideline Writing Committee
2014	AHA/ACC STEMI Practice Guideline Update Committee
2014-2015	AHA Scientific Publishing Committee
2014-present	Samuel Levine Young Investigator Award Committee
2016- 2016-present	AHA Research Leader's Academy Steering Committee Executive Editor <i>Circulation</i>
2011-2012	Society of Chest Pain Centers
2011-2012	Board of Trustees

Grant Review Activities

Year(s)	Name of Review Committee	Organization
2005	Peer Reviewer	Health Services R&D Awards, Ireland
2006	Peer Reviewer	VA Merit Awards

2007	Peer Reviewer	UK National Health Service, UK
2007-2009	Pilot Awards Program	North and Central Texas Clinical and Translational Science Initiative (NCTCTSI)
2007-2012	ACC Foundation Research Awards Review committee	American College of Cardiology
2008	Peer Reviewer	Catalan Agency for Health Technology Assessment and Research, Spain
2008	Annual Contestable Funding Round	Health Resource Council of New Zealand
2009	Peer Reviewer, Challenge Grants	NIH
2010-2014	SBIR Study Section (ZRG1 CVRS-B 10 B, Small Business: Cardiovascular Sciences)	NIH
2011	2012/01 ODCS Oral, Dental and Craniofacial Sciences Study Section, ad hoc member	NIH
2011	Annual Contestable Funding Round	Health Research Council of New Zealand
2012	Clinical and Integrative Cardiovascular Sciences (CICS) Study Section, ad hoc member	NIH
2012	ERC Starting Grant 5 th Call 2012	European Research Council
2014	NHLBI Special Emphasis Panel to Review Framingham Heart Study contract	NIH
2014	Pilot Award Review Committee	Center for Translational Medicine, UT Southwestern
2014	NHLBI Division of Intramural Research Site Visit	NIH
2015	Pilot Grants Committee	Department of Internal Medicine, UT Southwestern
2015	Genome/Phenome Predictors in CVD Grant Review Committee	AHA
2015	UK National Institute for Health Research	UK National Institute for Health Research
2018	NHBLI Special Review Panel for Cardia Study	NIH

Editorial Activities

Year(s)	Journal Name
<u>Editor/Associate Editor</u>	
2010-2013	<i>Cardioexchange.com (Fellowship section co-editor)</i>
2016-	Executive Editor, <i>Circulation</i>

Editorial Board

	<i>Circulation (past)</i>
--	---------------------------

9

	<i>Journal of the American College of Cardiology (past)</i>
	<i>The American Journal of Cardiology (past)</i>
	<i>The American Heart Journal (past)</i>
	<i>Cardiology in Review (past)</i>

Ad Hoc Reviewer

	<i>New England Journal of Medicine</i>
	<i>Journal of the American Medical Association</i>
	<i>The Lancet</i>
	<i>Nature Medicine</i>
	<i>Circulation</i>
	<i>Circulation specialty journals including Circulation Heart Failure, Genetics, Quality/Outcomes, Interventions)</i>
	<i>Circulation Research</i>
	<i>Journal of the American College of Cardiology (Elite Reviewer 2006,2007,2008,2009)</i>
	<i>JACC specialty journals including JACC Imaging, Interventions, and Heart Failure</i>
	<i>The American Heart Journal</i>
	<i>The American Journal of Cardiology</i>
	<i>European Heart Journal</i>
	<i>Heart</i>
	<i>Clinical Chemistry</i>
	<i>Archives of Internal Medicine</i>
	<i>American Journal of Medicine</i>
	<i>Annals of Internal Medicine (Distinguished Reviewer 2005)</i>
	<i>Atherosclerosis</i>
	<i>Atherosclerosis, Thrombosis, and Vascular Biology</i>
	<i>Kidney International</i>
	<i>Clinical and Experimental Medicine</i>
	<i>Coronary Artery Disease</i>
	<i>Journal of Cardiac Failure</i>

Grant Support

<u>Present</u>	<i>Grantor: NIH/NHLBI 1R01HL144112-01</i>
2018-2021	<i>Title of Project: Biomarkers of myocardial injury, blood pressure and cardiovascular outcomes in SPRINT</i>
	<i>Role (Principal Investigator, Co-Investigator): Co Investigator (Berry, PI)</i>

	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 1,339,715 8/18-7/21
	This grant will determine whether intensive blood pressure control modifies cardiac injury and whether biomarkers can be used to guide the intensity of blood pressure lowering.

<u>Present</u>	<i>Grantor:</i> Roche Diagnostics
2018-2019	<i>Title of Project:</i> Cardiac Biomarkers in the HEART-D Trial
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 11/18-12/19
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$40,000
	This grant will determine whether a randomized fitness intervention modifies biomarkers of cardiac injury and neurohormonal stress.

<u>Present</u>	<i>Grantor:</i> NIH/NCATS UL1TR001105
2013-2019	<i>Title of Project:</i> UT Southwestern Clinical and Translational Alliance for Research (UTSTAR)
	<i>Role (Principal Investigator, Co-Investigator):</i> Core 2 (Discovery in Humans) Co-PI
	<i>Annual amount and date (direct costs only):</i> 2013 -2018 \$4,412,465
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	The objective of this project is to improve the way biomedical research is conducted across the country, reduce time it takes for laboratory discoveries to become treatments for patients, improve population health, and train a new generation of clinical and translational researchers. Dr. de Lemos' role on this project is to co-direct one of four cores, the Discovery in Humans core Role: Co-PI

<u>Present</u>	<i>Grantor:</i> Abbott Diagnostics (Investigator-initiated Grant)
2014-2019	<i>Title of Project:</i> High sensitivity troponin measurements in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2014-2016 \$170,000+materials
	This project will perform measurement of troponin I, using a novel highly sensitive assay, in the Dallas Heart Study with an aim of establishing this measurement as a valid tool for risk assessment in the general population.

<u>Present</u>	<i>Grantor:</i> Abbott Diagnostics (Investigator-initiated Grant)
2014-2019	<i>Title of Project:</i> Novel biomarker measurements in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i>

	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2014-2016 \$40,000+materials
	This project will measure selected novel cardiac biomarkers in the Dallas Heart Study as a compliment to the hs-cTnI project.

<u>Present</u>	<i>Grantor:</i> Abbott Diagnostics (Investigator-initiated Grant)
2014-2019	<i>Title of Project:</i> High Sensitivity Troponin I and BNP in the Jackson Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2014-2016 \$100,000+materials
	The study will prospectively evaluate, in a population-based cohort of African Americans, the associations between cardiac troponin I measured by a new highly sensitive troponin I assay (hs-cTnI), and BNP with incident congestive heart failure due to both systolic and diastolic dysfunction.

<u>Present</u>	<i>Grantor:</i> NIH/NIDDK 1 K23 DK106520-0
2015-2020	<i>Title of Project:</i> Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
	<i>Role (Principal Investigator, Co-Investigator):</i> Supervising Mentor for Ian Neeland MD
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$710,000
	This study will develop new MRI measures to assess adipose tissue function and apply them to the study of diabetes. I am the K23 mentor for the PI (Ian Neeland)

<u>Present</u>	<i>Grantor:</i> NIH/NHLBI (1T32HL125247)
2015-2020	<i>Title of Project:</i> Training in Cardiovascular Research
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-Principal Investigator
	<i>Annual amount and date (direct costs only):</i> N/A
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2015 -2020; \$1,926,228
	The objective of this institutional training grant is to select talented and committed young investigators and to prepare them for careers in cardiovascular research.

<u>Present</u>	<i>Grantor:</i> NIH/NHLBI 1 K23-HL131939
2016-2021	<i>Title of Project:</i> Cardiovascular disease prevention in the community: The role of risk factor screening and targeted health intervention in blood donors
	<i>Role (Principal Investigator, Co-Investigator):</i> Supervising Mentor for Maria Odette Gore, MD
	<i>Annual amount and date (direct costs only):</i> 150,000
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$750,000

	This study will develop and test a novel strategy for CVD screening and behavioral intervention among blood donors. I am the K23 mentor for the PI (Odette Gore)
--	--

<u>Past</u>	<i>Grantor:</i> American Heart Association
2013-2018	<i>Title of Project:</i> HFpEF Prevention Center
	<i>Role (Principal Investigator, Co-Investigator):</i> Training Director, Co-PI Population Science
	<i>Annual amount and date (direct costs only):</i> \$1,000,000
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$4,000,000
	This study formed a multidisciplinary research center focusing on preventing heart failure with preserved ejection fraction. It is one of four centers included in the AHA's Strategically Focused Prevention Network. I was Director of the training program for this multidisciplinary grant and co-PI of the epidemiology project.

<u>Past</u>	<i>Grantor:</i> National Space Biomedical Research Institute
2014-2017	<i>Title of Project:</i> Improving Cardiovascular Risk Prediction: Biomarkers and Beyond
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> N/A
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2014 -2018; \$1,386,000
	This study evaluated, in a series of population-based studies, novel risk stratification tools that combine biomarkers and imaging in an "astronaut-like" demographic. The goal is to improve prediction and assessment of cardiovascular risk in the young and middle aged population.
	The objective of this institutional training grant is to select talented and committed young investigators and to prepare them for careers in cardiovascular research.

<u>Past</u>	<i>Grantor:</i> Roche Diagnostics (Investigator-initiated Grant)
2011-2013	<i>Title of Project:</i> Correlation of Changes in Biomarkers with Incidence and Progression of Subclinical Cardiovascular Disease in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 2011-2013 \$159,432+ materials
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This project will perform measurement of novel biomarker in the return DHS visit and correlate serial changes with changes in cardiovascular phenotypes over an 8 year period.

<u>Past</u>	<i>Grantor:</i> Abbott Diagnostics (Investigator-initiated Grant) OTD-102615
2011-2013	<i>Title of Project:</i> Sensitive troponin measurements in cardiac transplant rejection and pulmonary hypertension
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 2011-2013 \$88,400+materials
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>

	This project will perform measurement of troponin T, using a novel highly sensitive assay, in two cohorts: one with cardiac transplant (to evaluate transplant rejection) and one with pulmonary hypertension.
--	--

<u>Past</u>	<i>Grantor:</i> Roche Diagnostics (Investigator-initiated Grant)
2009-2010	<i>Title of Project:</i> Highly sensitive troponin T in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 2009-2010 \$62,450
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This project evaluated a novel, highly sensitive assay for cardiac troponin T as a screening test for cardiovascular disease in the community

<u>Past</u>	<i>Grantor:</i> NHLBI SBIR Contract HHSN2682010 00003C Subcontract IOS #31 92-NIH-ACS
2009-2010	<i>Title of Project:</i> Lateral-flow immunoassay platform for multiplexed cardiac biomarkers measurement
	<i>Role (Principal Investigator, Co-Investigator):</i> Subcontract Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 2009-2010 \$169,997
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	The goal of this project was to develop a point of care test strip for cardiovascular biomarkers.

<u>Past</u>	<i>Grantor:</i> NIH/NHLBI T32HL007360-04
2008-2014	<i>Title of Project:</i> Training in Cardiovascular Research (Hill PI)
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-PI
	<i>Annual amount and date (direct costs only):</i> 2008-2014; \$846, 521
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> N/A
	The objective of this institutional training grant is to select talented and committed young investigators and to prepare them for careers in cardiovascular research

<u>Past</u>	<i>Grantor:</i> NIH ROI HL087768
2007-2012	<i>Title of Project:</i> The GoodNEWS Trial (De Haven PI)
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-Investigator
	<i>Annual amount and date (direct costs only):</i> 2007-2012
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$1,903,932
	This is a randomized controlled trial testing a community-based participatory intervention to lower cardiovascular risk in predominantly African American churches in Dallas.

<u>Past</u>	<i>Grantor:</i> NIH UL1RR024982
-------------	---------------------------------

2007-2012	<i>Title of Project:</i> North and Central Texas Clinical and Translational Science Initiative (Toto PI)
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-Investigator
	<i>Annual amount and date (direct costs only):</i> 2007-2012
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$22,000,000
	This award supported the initial UTSW CTSA.

<u>Past</u>	<i>Grantor:</i> Rules Based Medicine (Investigator-initiated Grant)
2007	<i>Title of Project:</i> Evaluation of a multiple biomarkers in a chest pain unit
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 2007 \$10,000
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This was a pilot study evaluating a large biomarker panel in a chest pain unit population.

<u>Past</u>	<i>Grantor:</i> Biosite, Inc. (Investigator-initiated Grant)
2006-2009	<i>Title of Project:</i> Biomarker Discovery in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2006-2009 \$255,000
	This is an ongoing discovery project designed to identify novel biomarkers of cardiovascular disease, with an ultimate goal of creating multiple biomarker panels for population screening.

<u>Past</u>	<i>Grantor:</i> Donald W. Reynolds Foundation
2006-2009	<i>Title of Project:</i> Return to the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-Investigator
	<i>Annual amount and date (direct costs only):</i> 2006-2009 \$6,622,722
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> \$6,622,722
	This grant supported the return visit for the Dallas Heart Study cohort

<u>Past</u>	<i>Grantor:</i> Glaxo-Smith-Kline (Investigator-initiated Grant)
2006	<i>Title of Project:</i> Evaluation of LP-PLA2 in the Dallas Heart Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> \$52,000 2006
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This project evaluated the associations between LP-PLA2, a novel inflammatory biomarker, and subclinical coronary and peripheral atherosclerosis.

<u>Past</u>	<i>Grantor:</i> Free Fatty Acid Sciences, Inc. (Investigator-initiated Grant)
2004	<i>Title of Project:</i> Development of Novel Biomarkers of Cardiac Ischemia

	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only): \$62,500 2004</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This study used a human model of cardiac ischemia (rapid atrial pacing) to evaluate unbound free fatty acid as a novel ischemia biomarker.

<u>Past</u>	<i>Grantor: Ischemia Technologies, Inc. (Investigator-initiated Grant)</i>
2004	<i>Title of Project: Development of Novel Biomarkers of Cardiac Ischemia</i>
	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only): \$12,500 2004</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This study used a human model of cardiac ischemia to evaluate Ischemia Modified Albumin as a novel ischemia biomarker

<u>Past</u>	<i>Grantor: Biosite, Inc. (Investigator-initiated Grant)</i>
2004	<i>Title of Project: Evaluation of a multiple biomarker panel to detect ischemia in a chest pain unit</i>
	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only): \$80,000 2004</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This project evaluated a poing of care device for biomarker measurement in the emergency room.

<u>Past</u>	<i>Grantor: Glaxo-Smith-Kline (Career Development Award)</i>
2003-2004	<i>Title of Project: Identification of Novel Protein Markers of Cardiac Ischemia</i>
	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only): \$100,000 20032004</i>
	This study developed a discovery platform for identifying and validating potential ischemia biomarkers.

<u>Past</u>	<i>Grantor: Roche Diagnostics (Investigator-initiated Grant)</i>
2003-2004	<i>Title of Project: NT-proBNP, hs-CRP, and cTnT in the Dallas Heart Study</i>
	<i>Role (Principal Investigator, Co-Investigator): Principal Investigator</i>
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):\$332,744 2003-2004</i>
	This study performed comprehensive evaluation of the cardiac and non-cardiac sources of variation of hs-CRP, cTnT, and NT-proBNP in the general population.

<u>Past</u>	<i>Grantor:</i> NIH 7 RO1 AT 0005-03
2002-2005	<i>Title of Project:</i> Effect of High Dose Alpha Tocopherol on Carotid Atherosclerosis
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-Investigator (10% effort)
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2002-2005
	The goal of this project was to evaluate the potential protective effects of vitamin E on carotid atherosclerosis

<u>Past</u>	<i>Grantor:</i> Merck and Co.
2001-2004	<i>Title of Project:</i> The A to Z Study
	<i>Role (Principal Investigator, Co-Investigator):</i> Co-Principal Investigator
	<i>Annual amount and date (direct costs only):</i>
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i> 2001-2004
	This was a two –phased multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of early intensive statin therapy in patients with acute coronary syndromes (phase Z). It also compared low molecular weight heparin vs unfractionated heparin (phase A).

<u>Past</u>	<i>Grantor:</i> Merck and Co. (Investigator-initiated Grant)
2001	<i>Title of Project:</i> Cost-effectiveness analysis of tirofiban in acute coronary syndromes
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> \$15,000 2001
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	A cost-effectiveness model was developed to evaluate tirofiban use in acute coronary syndromes

<u>Past</u>	<i>Grantor:</i> Pfizer (Investigator-initiated Grant)
2001	<i>Title of Project:</i> Prospective risk-factor intervention in a multi-ethnic population
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> \$60,000 2001
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>
	This study tested a pharmacist-based program for lipid management in an underserved population

<u>Past</u>	<i>Grantor:</i> Spectral Diagnostics
1998	<i>Title of Project:</i> Use of a rapid bedside assay for myoglobin to predict reperfusion after thrombolytic therapy: a substudy of the TIMI 14 trial
	<i>Role (Principal Investigator, Co-Investigator):</i> Principal Investigator
	<i>Annual amount and date (direct costs only):</i> 1998
	<i>Total amount of award (if multi-year) and dates (direct costs only):</i>

	A rapid bedside test for myoglobin was used for risk assessment and noninvasive detection of reperfusion success after fibrinolytic therapy.
<u>Past</u>	<i>Grantor:</i> Brigham and Women’s Hospital NIH Training Grant
1998-2000	<i>Title of Project:</i> Public Health Services Grant HL07604-13
	<i>Role (Principal Investigator, Co-Investigator):</i> Trainee
	From 1998-2000, specific portions of the budgets for operational direction of these trials (and substudies within these trials) were designated for my salary support.
	TIMI 14 - Centocor Inc., Eli Lilly & Co. InTIME-II - Bristol Myers Squibb TACTICS/TIMI 18 – Merck and Co. ER/TIMI 19 –Centocor Inc. FASTER – Merck and Co. INTEGRITI – Cor Therapeutics Inc, Schering-Plough Research Institute A2Z – Merck and Co. PROVE IT – Bristol Myers Squibb

Clinical Trials Activities

Local PI for Multiple Multicenter trials
Trial leadership activities listed above

Teaching Activities

<u>Year(s)</u>	<u>Activity</u>
<u>Medical and graduate school didactic and small group teaching</u>	
2000-present	Core didactic lectures to Cardiology Fellows on management of acute coronary syndromes, annual
2000-present	Cardiology Clinical Conference (30 min case-based lecture), annual
2004-present	Fellows Research Conference, moderator, weekly
2006-present	Core didactic lectures to Internal Medicine residents on principles of management of acute coronary syndromes, annual
2006-present	Core didactic lectures to Emergency Medicine residents, “Management of Non ST elevation Acute Coronary Syndromes,” annual since 2006
2006-present	Fellows Journal Club, moderator, weekly
2011-present	Fellows Case Conference, faculty leader/discussant, monthly
<u>Dissertation committees</u>	
2010	Keith Bernardo
<u>Qualifying examination committees</u>	
2015	Daniel Lindholm (Sweden): PhD Opponent
2017	Colleen Ruth, PhD examination committee (McMaster, Canada)

Committees concerned with medical and graduate student education

2000-2011	Curriculum Committee, Internal Medicine Residency Training Program
2002-2010	Acute Care Committee for Fourth Year Student Rotations
2005-2008	Committee to Evaluate Clinical Competence, Internal Medicine Training Program
2009	Clinical Science Education Committee, Institutional Five Year Plan
2012	Clinical Science Education Committee, Institutional Six Year Plan

Graduate student rotations

2000-2014	Parkland Cardiology Outpatient Clinic (Cardiology fellows clinic) Medical Director, 2000-2001 Attending physician, 2000-present (average 2 days/month)
2000-present	Parkland Cardiology Consult Service, average 2 weeks per year
2001-present	Coronary Care Unit Parkland Hospital Medical Director (2001-11) Attending physician (average 3 months per year)
2002-2014	St. Paul University Cardiology Service, average ½-1 month per year
2009-2013	UT Clinical Heart Center, preceptor for PA students, 6 days/year
2009-2014	St. Paul University Cardiology Consult Service, average 2 weeks/year

Medical student rotations

2000-2013	Parkland Cardiology Consult Service (4 th year elective), average 2 weeks per year
2001-present	Coronary Care Unit Parkland Hospital, Medical Director Attending physician (average 3 months per year)
2002-2011	Director Acute Care Clerkship in Cardiology
2009-2014	St. Paul University Cardiology Consult Service, average 2 weeks/year
2015	Distinguished Educator Award Nominee

College student trainees

2015	Walter Oliver
2015	Gwendolyn Matthews
2015	Kim Reimold
2018	Adriene Walker

Postdoctoral trainees

2000-2001	Stanley Watkins, MD
2003-2004	Amit Khera, MD, MS
2002-2004	Rajat Deo, MD
2003-2004	Vivian Mo, MD
2004-2005	Sandeep Das, MD, MPH
2004-2006	Shuaib Abdullah

2004-2006	Alice Chang, MD
2005-2006	Tom Wallace, MD
2005-2007	Usman Baber, MD
2005-2007	Rapheal See, MD
2004-2010	Shailja Parikh, MD
2006-2010	Sachin Gupta, MD
2007-2009	Anand Rohatgi, MD
2007-2009	Frances Wood, MD
2009-2010	Leticia Castillo, MD
2008-2009	Andrew Owens, MD
2008-2009	Nitin Gupta, MD
2009-2011	Tiffany Powell, MD, MPH
2010-2011	Ann Nguyen, MD
2010-2012	Lu Chen, MD, MPH
2011-2013	Ian Neeland, MD
2013-present	Purav Mody, MD
2015-present	Jeanney Lew, MD
2015-2016	Wally Omar, MD
2014-2016	Maria (Odette) Gore, MD
2015-2017	Elizabeth (Blair) Solow, MD
2015-2018	Ambarish Pandey, MD
2016-present	Eddie Hackler, MD
2016-2017	Josephine, Harrington, MD
2017-present	Chistopher Puleo, MD
2018-present	Christopher Wrobel, MD
2018-present	Alana Lewis, MD

Invited Lectures

Year(s)	Title	Location
<u>International</u>		
2000	Symposia, Tapai and Kowshon, Taiwan, "Statins in acute coronary syndromes	Tapai and Kowshon, Taiwan
2000	International Society of Atherosclerosis, Stockholm, Sweden, "Infection, Inflammation, and Statins in ACS	Stockholm, Sweden

2001	European Heart House University Program, Cannes, France. Management of the CHD Patient at Hospital Discharge. Lecture: “When Should Statins be Started Following an Acute Coronary Syndrome?”	Cannes, France
2002	Distinguished Speaker. Asociación Nacional de Cardiólogos de México. Multiple Lectures on various topics in Acute Coronary Syndromes	Acapulco, Mexico
2003	Mexican Society of Cardiology. Lectures on Acute MI, Reperfusion Therapy, Statin Agents in Acute Coronary Syndromes.	Monterrey, Mexico
2003	Invited Faculty, Cardiology Society of Sao Paulo, Sao Paulo Brazil. Multiple lectures on acute coronary syndromes and biomarkers	Sao Paulo, Brazil
2004	Invited Lecturer, Canadian Cardiovascular Society Scientific Sessions. Multiple Lectures on Acute Coronary Syndromes and Risk Stratification	Calgary, Canada
2004	Lecture series in Taipei, Kowshun, Taishung, Taiwan: “Contemporary management of acute coronary syndromes”	Taipei, Kowshun, Taishung, Taiwan
2005	“Novel Biomarkers.” Joint ESC/ACC Symposium at the European Society of Cardiology Meeting	Stockholm, Sweden
2008	6 th Annual Center for Heart Failure Research Symposium. “Biomarkers in the Dallas Heart Study.”	Oslo, Norway
2008	6 th International Symposium on NT-proBNP. “Cardiovascular Risk in General Populations.”	Baveno, Italy
2009	Society of Cardiology de Rio de Janiero, Brazil. Keynote Speaker: “Antiplatelet therapy in Acute Coronary Syndromes” and “Risk Stratification in Acute Coronary Syndromes.”	Rio de Janiero, Brazil
2010	Sao Paulo State Cardiology Society (SOCER) Annual Meeting. Keynote lecture on “Biomarkers of Atherothrombosis,” and second lecture “Targets for Lipid Lowering,”	Sao Paulo, Brazil
2011	Mexican Congress of Cardiology: “Sensitive Troponins” and “Biomarkers in Congestive Heart Failure”	Puerta Vallarta, Mexico

2011	University of Puerto Rico Veterans Hospital Grand Rounds “Using Biomarkers, Genetics and Imaging to Identify Candidates for Cardiovascular Prevention.”	San Juan, Puerto Rico
2012	3 rd World Psoriasis and Psoriatic Arthritis Conference: Keynote Lecture “Inflammatory mediators of atherosclerosis with relevance to psoriasis.”	Stockholm, Sweden
2013	Keynote Lecture, Vascular 2013: “Vascular Risk Factors Over the Course of the Lifetime.”	Montreal, Canada
2013	9 th International proCardio Symposium: “Biomarkers of Cardiac Stress and Injury”	Amsterdam, Netherlands
2014	12 th Annual Center for Heart Failure Research Symposium. “Biomarkers for heart failure prediction: a path forward to prevention?”	Oslo, Norway
2015	Great Wall Meeting, “Bringing new Science to Cardiovascular Risk Prediction”	Beijing, China

2015	Wuhan Cardiovascular Symposium, “Biomarkers, Imaging, and Genetics for Cardiovascular Disease Screening”	Wuhan, China
2015	Biomarker Symposium, Upsulla Center for Clinical Research	Upsulla, Sweden
2016	Research Symposium: “Screening the population for cardiovascular disease.”	Hangzhou China
2016	Oriental Congress of Cardiology: “Acute troponin level and the classification of MI”	Shanghai, China
2017	University of Alberta Grand Rounds and Dr. Joseph Dvorkin Memorial Lecture: “Predicting Cardiovascular Disease Risk Among Apparently Healthy Adults: Can We Build a Better Mousetrap?”	Edmonton, Canada
2018	“Appropriate Cardiac Testing,” and “Update in Acute Coronary Syndromes”	Rome Italy

National

2000	American Heart Association Annual Meeting: “How to assess myocardial reperfusion: invasive and noninvasive approaches.”	Ananheim, CA
2000	Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, “Redefining reperfusion in AMI: Optimizing microvascular flow, restoring myocardial metabolism—	Washington, DC

2000	Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, “Pathophysiology of plaque formation, regression, and rupture—Can statins interrupt natural history?”	Washington, DC
2000	State of the Art Lecture: The 4 th National Congress of Chest Pain Centers, Baltimore, MD, “The effects of combined thrombolytic and platelet inhibitor therapy on myocardial and microvascular perfusion.”	Baltimore, MD
2001	Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, “Harmonizing mechanical and pharmacologic therapies For Acute MI—Beyond TIMI 3 Flow: The role of static and continuous ECG Monitoring”	Washington, DC
2001	American College of Cardiology Board Review “Antiplatelet and Antithrombotic Agent in ACS”	Chicago, IL
2002	Fifth Annual Joint Summit on Markers in Cardiology. “Myoglobin, a “Blue Collar”	Louisville, KY

	Marker’s Application in Patients with Acute Coronary Syndromes	
2002	4 th Annual Mount Sinai Acute Coronary Syndromes Symposium. Lectures on “Serum Markers” and “Incorporating Combination Pharmacologic and PCI approaches for ST elevation MI”	New York, NY
2002	American College of Cardiology Board Review Course, “Antiplatelet and Antithrombotic Agent in Acute Coronary Syndromes	Chicago, IL
2002	Emerging Science of Lipid Management, Regional Co-Chair	New York, NY
2002	Grand Rounds, Geisinger Medical Center, Danforth PA: “Advances in Antithrombotic Therapy for Acute Coronary Syndromes	Danforth, PA
2003	AHA Satellite Symposium: “ Standards in ACS from Diagnosis to Discharge.” Lecture: “Novel Cardiac Markers: sCD40L, BNP, and Multimarker Approaches	Orlando, FL
2003	Transcatheter Therapeutics Meeting, Invited Faculty. “New Tools for Risk Stratification in ACS” and “Enoxaparin in ACS	Washington, DC

2003	College of American Pathologists: “Troponin, the natriuretic peptides and other biochemical markers: understanding heart disease.	San Diego, CA
2003	American College of Cardiology Board Review Course: “ST Elevation MI” and “Antithrombotic Therapies	Chicago, IL
2003	Emerging Science of Lipid Management, Regional Co-Chair	New York, NY
2003	Cardiology Grand Rounds, The University of Michigan Medical School: “Novel Cardiac Markers for Risk Stratification in Acute Coronary Syndromes	Ann Arbor, MI
2003	Cardiology Grand Rounds, Tulane University Medical School. “Integrating Risk Stratification into Clinical Decision Algorithms for Acute Coronary Syndromes”	New Orleans, LA
2003	Cardiology Grand Rounds, Vanderbilt Medical Center, Nashville TN “Biomarkers in Ischemic Heart Disease: Integrating Pathophysiology and Risk Stratification	Nashville, TN
2003	American College of Cardiology Symposium “Cardiology at Big Sky.” Lectures on	Big Sky, MO

	“Management of ST elevation MI” and “Antiplatelet and Antithrombotic Therapies	
2003	Vascular Biology Working Group. “Novel Cardiac Biomarkers for Risk-Stratification in Patients with Acute Coronary Syndromes	Chicago, IL
2004	AHA Symposium, Risk Stratification in Acute Coronary Syndromes, “Natriuretic Peptides in ACS”	New Orleans, LA
2004	Cardiac Marker Summit, “Natriuretic Peptides in Ischemic Heart Disease	Louisville, KY
2004	Transcatheter Therapeutics Meeting, Symposium Chair “Cardiac Markers,” and lecture, “Enoxaparin in Acute Coronary Syndromes	Washington, DC
2004	College of American Pathologists National Meeting: “Clinical Applications of Cardiac Biomarkers	Phoenix, AZ
2004	American College of Cardiology Board Review Course, Atlanta, GA 2 lectures and case presentations about acute coronary syndromes and antithrombotic therapies	Atlanta, GA

2004	5 th Annual Antithrombotic Therapy Symposium, Detroit. “Adjunctive Therapies for STEMI	Detroit, MI
2004	Symposium Chair, American College of Cardiology Meeting, New Orleans. “Markers of Atherogenic Risk: The Old and the New	New Orleans, LA
2005	Plenary Lecture, American Heart Association Scientific Sessions “Challenges in Acute Coronary Syndromes: Biomarkers and Diagnosis.”	New Orleans, LA
2005	Invited lecture, Washington University, St. Louis, MO “Biomarkers in Acute Coronary Syndromes.”	St. Louis, MO
2005	University of Kansas Cardiovascular Symposium. Keynote Speaker: “Acute Coronary Syndromes” and “Acute Myocardial Infarction	Wichita, KS
2006	AHA Scientific Sessions, Invited Symposium Lecture. “Multiple Biomarker Strategies for Risk Stratification in the Acute Coronary Syndromes.”	Orlando, FL
2006	Cardiology Grand Rounds, Oschner Medical Center, New Orleans LA. “Management of the Acute Coronary Syndromes.”	New Orleans, LA

2006	Cardiology Grand Rounds, Tulane Medical Center, New Orleans LA; “Antiplatelet and Antithrombotic Strategies in ACS”	New Orleans, LA
2006	University of Virginia 19 th Annual Seminar on Advances in Cardiovascular Medicine, Charlottesville, VA: “Cardiac markers and their clinical significance.”	Charlottesville, VA
2006	Boehringer Ingelheim Expert Panel on Atherosclerosis, New York, NY: “Clinical development of novel therapies for atherosclerosis: the role of biomarkers, imaging and surrogate endpoints.”	New York, NY
2006	2006 Biomarker Symposium with FDA, Bethesda MD: “Biomarkers of Congestive Heart Failure.”	Bethesda, MD
2006	Cardiology Grand Rounds, Yale Medical School, New Haven CT: “Antiplatelet and antithrombotic strategies in ACS.”	New Haven, CT

2006	American College of Physicians Symposium, Philadelphia on “Prevention of atherothrombotic disease.” Lecture: “Diagnostic Pathways to Atherothrombotic Disease: Identifying High Risk Patients.”	Philadelphia, PA
2006	Symposium: “Risk Stratification in ACS,” at ACC Scientific Sessions, Atlanta Topic: “Biomarkers”	Atlanta, GA
2007	Cardiology Grand Rounds, SUNY Stonybrook. “Acute Coronary Syndromes: an update.	Stoneybrook, NY
2007	Cardiology Grand Rounds, Grady Memorial Hospital. “Antiplatelet agents in acute coronary syndromes: old problems, new drugs.”	Atlanta, GA
2007	Cardiology Grand Rounds, University of Michigan Medical Center. “Biomarkers in Cardiovascular Disease: First steps in the move to personalized medicine?”	Ann Arbor, MI
2007	American Heart Association Plenary Lecture: “Antithrombotic Therapy in ACS from Door to Discharge”	Orlando, FL
2007	2007 NHLBI/FDA Biomarker Symposium “Biomarkers of Congestive Heart Failure.”	Bethesda, MD
2007	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents,”	Las Vegas, NE
2007	4 th Symposium on the Burden of Atherothrombotic Disease: Diagnosis and Therapy. Lecture: “The Dallas Heart Study.”	New York, NY
2007	AHA Satellite Symposium on <u>Biomarkers in Acute Coronary Syndromes</u> . Lecture “Troponins Tried and New.”	New Orleans, LA
2007	Internal Medicine Grand Rounds, The University of Hawaii. “Biomarkers in Cardiovascular Disease: moving towards a personalized medicine approach.”	Honolulu, HA
2007	UCSD Biomarker Summit. “Biomarkers in the Dallas Heart Study.”	San Diego, CA
2008	Cardiology Grand Rounds, Case Western Reserve. “Biomarkers in Cardiology: promises and pitfalls	Cleveland, OH
2008	Cardiology Grand Rounds, University of California, Davis. “Biomarkers for Risk Assessment in the General Population	Sacramento, CA

2008	17th Annual Cardiology update for Primary Care. “What are appropriate lipid targets for 2008?”	Omaha, NE
2008	24 th Annual Cardiology Conference. “The emerging role of biomarkers in cardiovascular disease: present status and future challenges	Sioux City, IA
2008	Critical Markers of Disease Symposium. “Biomarkers of Thrombosis,” and “Population Screening.”	Bethesda, MD
2008	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents”	Las Vegas, NE
2008	3 rd International Symposium on Integrated Biomarkers In Cardiovascular Disease. “Biomarkers and Genetics for the Detection of Preclinical Heart Disease: insights from the Dallas Heart Study.”	Seattle, WA
2008	The 9 th Annual Antithrombotic Therapy Symposium. Eberhart Memorial Lecture in Coagulation Sciences “Biomarkers of Atherosclerosis and Thrombosis.”	Detroit, MI
2008	University of California San Diego Biomarker Summit. “Biomarkers in the Dallas Heart Study.”	San Diego, CA
2009	The 35 th Annual Williamsburg Conference on Heart Disease. “Diagnosis and Risk Assessment	Williamsburg, VA

	of Acute Coronary Syndromes” and “Early Lessons from the Dallas Heart Study	
2009	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents	Las Vegas, NE
2009	Institute of Medicine Committee on Qualification of Biomarkers as Surrogate Endpoints in Chronic Disease. Lecture: “Troponin as a Case Study for Cardiac Biomarkers	Washington, DC
2009	American College of Cardiology Satellite Symposium. “Realities of Contemporary Angina Management	Orlando, CA
2009	Cardiology Grand Rounds, University of Pennsylvania, “Biomarkers in Cardiovascular Disease: a paradigm for personalized medicine?”	Philadelphia, PA

2009	Research Seminar, University of Pennsylvania, “Biomarkers in the Dallas Heart Study.”	Philadelphia, PA
2009	Atherosclerotic Cardiovascular Disease from Pathophysiology to Management: New Insights, Symposium at Cedars Sinai Medical Center. “Non Traditional Risk Factors—from CRP to Gene Polymorphisms: Do They Really Help?”	Los Angeles, CA
2010	Visiting Professor, University of Wisconsin. Cardiology Grand Rounds: “Biomarkers in Cardiovascular Disease.” Internal Medicine Grand Rounds: “Controversies in Antiplatelet Therapy for Acute Coronary Syndromes	Madison, WI
2010	AHA Quality, Outcomes Research Meeting, “Utility of Biomarkers to Enhance CVD Risk Prediction	Washington, DC
2010	Keynote Debate, American Heart Association Epidemiology Annual Meeting. “Pro: Novel Risk Markers and Screening Tests Will Improve the Prediction and Prevention of Cardiovascular Disease	San Francisco, CA
2010	Cardiology Grand Rounds, University of Minnesota. “Biomarkers in Cardiovascular Disease: A Paradigm for Personalized Medicine	Minneapolis, MN
2011	AHA Scientific Sessions; “Risk Models and Biomarkers in ACS”	Orlando, FL
2011	Cadiometabolic Health Congress: “Biomarkers of Cardiac Stress and Injury”	Boston, MA
2011	Cardiology Grand Rounds, Brigham and Women’s Hospital. “Sensitive troponin assays: one step forward, two steps back?”	Boston, MA
2011	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents	Chicago, IL
2011	Vascular Biology Working Group Meeting: “Plasma Biomarkers: what about a multiple biomarker strategy	New Orleans, LA
2011	California Pacific Hospital Cardiology Grand Rounds. “Biomarkers for Risk Assessment in Cardiology	San Francisco, CA
2012	Grand Rounds, Penn State Medical Center: “Biomarkers in cardiovascular disease: promises, pitfalls, and practical solutions.”	Hershey, PA

2012	Association of University Cardiologists Annual Meeting: “Screening the population for heart disease using highly sensitive troponin assays.”	Carmel, CA
2012	AHA Satellite Symposium: “Stable angina; role of medical therapy and revascularization.”	Los Angeles, CA
2012	UCSD Biomarker Symposium: “Dallas Heart Study: Measuring low level cardiac injury in the general population	San Diego, CA
2012	ACC Clinical Focus Session Chair: “Rapid Fire Update in ACS.”	Chicago, IL
2012	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents	Chicago, IL
2013	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents	Chicago, IL
2013	The 39 th Annual Williamsburg Conference on Heart Disease. “Screening healthy individuals for heart disease: where are we and where are we going?”	Williamsburg, VA
2013	Donald W. Chapman Memorial Lecture, Baylor College of Medicine Cardiology Grand Rounds. “Highly sensitive assays for cardiac troponins”	Houston, TX
2013	Thomas W. Smith MD Memorial Lecture, Brigham and Women’s Hospital 2013 Cardiovascular Medicine Course. “Advances in Cardiac Biomarker Science: Implications for the Practitioner”	Boston, MA
2013	Best of ACC 2013 Update Meetings. “Acute Coronary Syndromes”	Chicago, IL Boston, MA

2013	ACC Clinical Focus Session Chair: “Rapid Fire Update in ACS.”	San Francisco, CA
2013	ACC Scientific Sessions: Debate: “High sensitivity troponin assays will drive the cardiologist to drink.”	San Francisco, CA
2014	AHA Symposium: “ACS Headline Debates: An Expert Exchange Regarding the Top Questions in Antiplatelet Therapy,” Program Chair	Chicago, IL
2014	AHA Scientific Sessions Lecture: “The changing face of the coronary care unit.””	Chicago, IL
2014	ACC Board Review Course. Lectures on “Non ST Elevation Acute Coronary Syndromes” and “Pharmacology of Antithrombotic Agents	Chicago, IL

2014	Best of ACC 2014 Update Meetings. “Acute Coronary Syndromes”	Anaheim, CA Chicago, IL
2014	Cardiology Grand Rounds, Mid America Heart Institute. “Highly sensitive troponin assays”	Kansas City, Mo
2014	ACC Scientific Sessions: “Innovation in antiplatelet therapy for ACS: can we improve efficacy without causing bleeding?”	Washington DC
2014	ACC Clinical Focus Session Chair: “Key controversies in ACS.”	Washington DC
2015	University of Utah: “Highly sensitive troponin assays: one step back and two steps forward?”	Salt Lake City, UT
2015	University of Arizona: “Highly sensitive troponin assays: new opportunities amid existing challenges	Tucson, AZ
2015	Best of ACC 2014 Update Meetings. “Acute Coronary Syndromes”	Miami, FL Chicago, IL
2015	AHA Late Breaking Clinical Trials: Discussant: “Individualizing Treatment Duration of Dual Antiplatelet therapy after PCI: An analysis of the DAPT trial.”	Orlando, FL
2015	CVCT meeting: Incorporation of Biomarkers into Clinical Trial Design	Washington, DC
2016	Cardiology Grand Rounds, Case Western Reserve University. “Acute Coronary Syndromes. Applying New Evidence to Clinical Practice”	Cleveland, OH
2016	Cardiology Grand Rounds, University of Chicago. “New Insights into the Epidemiology of Heart disease: a few stories from the Dallas Heart Study”	Chicago, IL

2016	Cardiology Grand Rounds, Christiana Health. “Screening the Population for Cardiovascular Disease: bringing new science to an old problem.”	Newark, DE
2016	Boston University Medical Center Cardiology Grand Rounds: Improving Outcomes in Acute Coronary Syndromes: From Even to Exit and Beyond	Boston, MA
2016	Beth Israel Deaconess Medical Center Cardiology Grand Rounds; Screening the Population for Cardiovascular Disease: Bring New Science to an Old Problem	Boston, MA

2017	Stonybrook Medical Center Internal Medicine Grand Rounds: “Update in the management of acute coronary syndromes”	Stonybrook, NY
2017	Plenary Lecture, University of Missouri Cardiovascular Medicine Annual Update	Columbia, MO
2017	Dennis Memorial Lecture, Baylor College of Medicine: “New approaches for cardiovascular risk assessment in the population.”	Houston TX
2017	AHA Scientific Sessions: “Managing the Troponin Tsunami” and “Practical considerations with implementation of hs-cTnT in the U.S.”	Anaheim, CA
2018	UCSD Biomarker Symposium: Debate on high sensitivity troponin testing	San Diego, CA
2018	ACC Scientific Sessions: “Implementing high sensitivity troponin into clinical practice	Orlando, FL
2018	Cardiology Grand Rounds, Cleveland Clinic. “High Sensitivity Troponins: New challenges, new opportunities”	Cleveland, OH
2018	ACC Annual Cardiology Board Review Course: “NSTEMI,” and “STEMI” lectures	Chicago, IL
2018	Cardiometabolic Health Conference: “Adding biomarkers to CAC scanning for global CVD risk assessment”	Boston, MA
2018	PRIMED regional meeting; “Update in Acute Coronary Syndromes”	Los Angeles, CA
2018	ACC/NIH/NIA Symposium on Cardiac Testing in the Elderly: “Biomarker Considerations in Older Adults.”	Washington DC
2019	ACC Scientific Sessions: “Prevention Year in Review.”	New Orleans, LA

2019	ACC Scientific Sessions: “Why hs-cTn is important to your practice.”	New Orleans, LA
2019	Cardiology Grand Rounds, University of Alabama Birmingham: “Screening the population for cardiovascular disease: can we create a better mousetrap?”	Birmingham, AL

Regional/Local

2003	Cardiology Grand Rounds, Wilford Hall Medical Center. “Recent Advances in Acute Coronary Syndrome Diagnosis and Management	San Antonio, TX
------	--	-----------------

2004	Texas Heart Institute Grand Rounds (2 lectures) “Novel Applications of Cardiac Biomarkers in Acute Coronary Syndromes” and “BNP in Cardiovascular Disease	Houston, TX
2004	Medicine Grand Rounds, UT Tyler Medical Center: “Advances in Antithrombotic Therapy for Acute Coronary Syndromes.”	Tyler, TX
2005	Internal Medicine Grand Rounds, Baylor University Medical Center, Dallas, TX “Biomarkers in Cardiovascular Disease: integrating pathophysiology into clinical practice	Dallas, TX
2005	American College of Cardiology Board Review Course, Two lectures and case presentations	Dallas, TX
2006	Cardiology Fiesta, San Antonio Texas: “Statins and Pleiotropic Effects” and “Biomarkers for Individualizing Therapy	San Antonio, TX
2007	Cardiology Fiesta. Lectures: “Lessons for San Antonio from the Dallas Heart Study” and “Biomarkers in Cardiovascular Disease.”	San Antonio, TX
2008	Cardiology Fiesta. “Lessons from the Dallas Heart Study.”	San Antonio, TX
2008	UT Southwestern Preventive Cardiology Symposium. “New Goals for Lipid Lowering Therapy.”	Dallas, TX
2008	Southwest Cardiology Summit. “Controversies in Antiplatelet Therapy.”	Dallas, TX
2009	Cardiology Fiesta 2009 Symposium, “Translating Research Studies into Clinical Practice: my top 10 suggestions	San Antonio, TX
2009	Texas Tech University First Annual Update in General Internal Medicine. Keynote address: “Biomarkers, Imaging, and Genetics: Ready for my primary care practice?”	Lubbock, TX
2010	Cardiology Fiesta. Lectures on “Protein Biomarkers in Heart Disease,” and “How to develop a career in academic cardiology	San Antonio, TX
2010	Baylor Cardiovascular Summit. “How to choose an antiplatelet agent for my patient”	Dallas, TX
2011	Texas Heart Institute Cardiology Grand Rounds. “Biomarkers in Cardiovascular Disease: focus on population screening	Houston, TX

2012	Cardiovascular Innovations Symposium, UT Southwestern: “Antiplatelet and Antithrombotic Agents in ACS.”	Dallas, TX
2012	Tyler Cardiovascular Summit, Keynote Address: “Screening healthy individuals for heart disease: where are we and where are we going?”	Tyler, TX
2012	Internal Medicine Grand Rounds, UT Southwestern: Increasingly Sensitive Assays for Cardiac Troponins: One Step Back and Two Steps Forward?	Dallas, TX
2012	Cardiology Grand Rounds, UT Health Science Center, San Antonio. “Sensitive troponin assays pitfalls and progress.”	San Antonio, TX
2013	Cardiology Grand Rounds, Baylor Medical Center: “Antiplatelet agents in ACS.”	Dallas, TX
2016	Grand Rounds, Texas Health Resources: “Update in Acute Coronary Syndromes”	Dallas, TX
2016	Department Conference, UT Southwestern: Predicting Cardiovascular Risk Among Apparently Healthy Adults: Can we Build a Better Mousetrap	Dallas, TX
2017	Grand Rounds, Methodist Hospital, “Antiplatelet therapy after ACS and PCI: How long and how strong?”	Dallas, TX
2018	UTW Update in Internal Medicine: “High sensitivity troponin testing for rapid rule out of MI”	Dallas TX
2018	Texas Health Resources Symposium: “High sensitivity troponin testing: maximizing the gain and minimizing the pain”	Dallas TX

Technological and Other Scientific Innovations

None

Service to the Community

None

Bibliography

Peer-Reviewed Publications

Original Research Articles

1.	de Lemos JA , Dryer G, Gerstmann DR, de Lemos RA. Oliguria in the premature baboon with hyaline membrane disease: a manifestation of multisystem immaturity. <i>J Perinatol</i> 1989;9:1925. PMID:2651593.
2.	de Lemos RA, Roberts RJ, Coalson JJ, de Lemos JA , Null DM, Gerstmann DR. Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. <i>Am J Dis Child</i> 1990;144:915-9. PMID:2378340.
3.	de Lemos RA, Coalson JJ, de Lemos JA , King RJ, Clark RH, Gerstmann DR. Rescue ventilation with high frequency oscillation in premature baboons with hyaline membrane disease. <i>Pediatr Pulmon</i> 1992;12:29-36. PMID:1579373.
4.	de Lemos JA , Antman EM, Giugliano RP, McCabe CH, Murphy SA, Gibson CM, Braunwald E, for the TIMI 14 Investigators. ST resolution and infarct related artery patency and flow after thrombolytic therapy. <i>Am J Cardiol</i> 2000; 85:299-304 PMID:11078296.
5.	de Lemos JA , Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey M, Van der Wieken R, Van de Werf F, MD, Braunwald E, for the TIMI 14 Investigators. Abciximab improves both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: observations from the TIMI 14 trial. <i>Circulation</i> 2000; 101:239-43 PMID:10645918.
6.	Morrow DA, Rifai N, Tanasijevic MJ, Wybenga DR, de Lemos JA , Antman EM. Clinical efficacy of three assays for cardiac troponin I and risk stratification in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11B substudy. <i>Clin Chem</i> 2000; 46:453-60. PMID:10759468.
7.	de Lemos JA , Antman EM, Morrow DA, Llevadot J, Giugliano RP, Coulter SA, Schuhwerk KC, Arslanian S, McCabe CH, Gibson CM, Rifai N. Heart-type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy. <i>Clin Chimica Acta</i> 2000; 298:85-97. PMID:10876006.
8.	de Lemos JA , Hennekens CH, Ridker PM. Plasma concentration of soluble Vascular Cell Adhesion Molecule-1 and subsequent cardiovascular risk. <i>J Am Coll Cardiol</i> 2000; 36:423-6. PMID:10933352.
9.	de Lemos JA , Antman EM, Giugliano RP, Morrow DA, McCabe CH, Charlesworth A Schröder R, Braunwald E, for the InTIME II Investigators. Very early risk stratification after thrombolytic therapy using a bedside myoglobin assay and the 12-lead ECG. <i>Am Heart J</i> 2000; 140:373-8. PMID:10966533.
10.	Morrow DA, Antman EA, Charlesworth A, Cairns R, Murphy SA, de Lemos JA , Giugliano RP, McCabe C, Braunwald E. The TIMI Risk Score for ST elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an InTIME II substudy. <i>Circulation</i> 2000 102:2031-7. PMID:11044416.
11.	Antman EM, Gibson CM, de Lemos JA , Giugliano RP, McCabe CH, Coussement P, Menown I, Mienaber CA, Rehders TC, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the TIMI 14 Investigators. Combination reperfusion therapy
	with abciximab and reduced dose reteplase: results from TIMI 14. <i>Eur Heart J</i> 2000;21:1944-53. PMID:11071800.
12.	Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA , McCabe CH, Cannon CP, Braunwald E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy. <i>J Am Coll Cardiol</i> 2000; 36:1812-7. PMID:11092649.

13.	de Lemos JA , Antman EM, Giugliano RP, Morrow DA, McCabe CH, Cutler SS, Charlesworth A, Schröder R, Braunwald E, for the InTIME-II Investigators. Comparison of a 60- vs 90minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. <i>Am J Cardiol</i> 2000; 86:1235-7. PMID:11090796.
14.	de Lemos JA , Gibson CM, Antman EM, Murphy SA, Schuhwerk, KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E, for the TIMI 14 Investigators. Abciximab and Early Adjunctive Percutaneous Coronary Intervention are Associated With Improved STsegment Resolution After Thrombolysis: observations from the TIMI 14 trial. <i>Am Heart J</i> 2001;141:592-8. PMID:11275925.
15.	Gibson CM, Kirtane AJ, Murphy SA, Marble SJ, de Lemos JA , Antman EM, Braunwald E for the TIMI Study Group. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. <i>Catheter Cardiovasc Interv</i> 2001;53(1):6-11. PMID:11329210.
16.	Gibson CM, de Lemos JA , Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. <i>Circulation</i> 2001;103:2550-4. PMID:11382722.
17.	Srinivas VS, Cannon CP, Gibson CM, Antman EM, Greenberg MA, Tanasijevic MJ, Murphy S, de Lemos JA , Sokol S, Braunwald E, Mueller HS. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. <i>Am Heart J</i> . 2001 Jul;142(1):29-36. PMID:11431653.
18.	de Lemos JA , Morrow DA, Gibson CM, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald E, for the TIMI 14 Investigators. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. <i>Am J Cardiol</i> 2001 88:353-8. PMID:11545753.
19.	Morrow DA, Antman EM, Giugliano RP, Parsons L, de Lemos JA , McCabe CH, Barron HV, Braunwald E. Application of the TIMI Risk Score for ST Elevation Myocardial Infarction for mortality prediction in the National Registry of Myocardial Infarction. <i>JAMA</i> 2001; 286:13569. PMID:11560541.
20.	de Lemos JA , Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. <i>N Engl J Med</i> 2001; 345:1014-1021. PMID:11586953.
21.	Morrow DA, Antman EM, Giugliano RP, Charlesworth A, Cairns R, Murphy SA, de Lemos JA , McCabe CH, Braunwald E. A simple risk index for rapid initial triage of patients with ST elevation MI: An InTIME II substudy. <i>Lancet</i> 2001; 358:1571-5. PMID:11716882.
22.	Omland T, de Lemos JA , Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal Pro-Atrial and Pro-Brain Natriuretic Peptide in patients with acute coronary syndromes: A TIMI 11B substudy. <i>Am J Cardiol</i> 2002; 89:463-5. PMID:11835931.
23.	Sabatine MS, Morrow DA, de Lemos JA , Gibson CM, Murphy SA, McCabe CH, Antman EM, Cannon CP, Braunwald E. A Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-type Natriuretic Peptide. <i>Circulation</i> 2002 105:1760-63 PMID:11956114.

24.	Antman EM, Cooper HA, Gibson CM, de Lemos JA , McCabe CH, Giugliano RP, Coussement P, Murphy S, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction: insights from TIMI 14 and InTIME-II. <i>Eur Heart J</i> 2002; 23:928-33. PMID:12069446.
25.	Sabatine MS, McCabe CH, Morrow DA, Giugliano RP, de Lemos JA , Cohen M, Antman EM, Braunwald E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. <i>Am Heart J</i> 2002; 143:966-70. PMID:12075250.
26.	Morrow DA, Antman EM, Sayah A, Schuhwerk KC, Giugliano RP, de Lemos JA , Waller M, Cohen SA, Rosenberg DA, Cutler SS, McCabe CM, Walls RM, Braunwald E. Evaluation of the Time Saved by Pre-hospital Initiation of Reteplase for ST Elevation MI: Results of the Early Retavase (ER) TIMI 19 Trial. <i>J Am Coll Cardiol</i> 2002; 40:71-7. PMID:12103258.
27.	de Lemos JA , Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of serum myoglobin in patients with non-ST segment elevation acute coronary syndromes: results from the TIMI 11B and TACTICS-TIMI 18 studies. <i>J Am Coll Cardiol</i> 2002; 40:238-44. PMID:12106926.
28.	Angeja BG, de Lemos JA , Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson CM, for the TIMI Study Group. The impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. <i>Am Heart J</i> 2002;144:649-56. PMID:12360161.
29.	Cooper HA, de Lemos JA , Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM, Braunwald E. Minimal ST-segment deviation: a simple, noninvasive method to identify patients with a patent infarct-related artery following fibrinolytic administration. <i>Am Heart J</i> 2002; 144:790-5. PMID:12422146.
30.	Gibson CM, de Lemos JA , Murphy SA, Marble SJ, Dauterman KW, Michaels A, Barron HV, Antman EM; TIMI Study Group. Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction. <i>J Thromb Thrombolysis</i> . 2002; 14:233-7. PMID:12913404.
31.	de Lemos JA , Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. The Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-term Clinical Outcomes in Patients with Acute Coronary Syndromes. <i>Circulation</i> . 2003 Feb 11;107(5):690-5. PMID:12578870.
32.	Morrow DA, de Lemos JA , Sabatine MS, Murphy SA, Demopolous LA, DiBattiste PM,McCabe CH, Gibson CM, Cannon CP, and Braunwald E. Evaluation of B-type Natriuretic Peptide for Risk Assessment in UA/NSTEMI: BNP and Prognosis in TACTICS-TIMI 18. <i>J Am Coll Cardiol</i> 2003; 41:1264-72. PMID:12706919.
33.	Murphy SA, Dauterman, K, de Lemos JA , Kermgard S, Antman EM, Braunwald E, Gibson CM. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. <i>Am Heart J</i> 2003;146:42-7. PMID:12851606.
34.	Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, de Lemos JA , Braunwald E, Cannon CP. Evaluation of the AccuTnI assay for cardiac troponin I for risk assessment in acute coronary syndromes. <i>Clin Chem</i> 2003; 49:1396-8. PMID:12881457.
35.	Varo N, de Lemos JA , Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. <i>Circulation</i> 2003;108:1049-52. PMID:12912804.

36.	Karha J, Murphy SA, Kirtane AJ, de Lemos JA , Aroesty JM, Cannon CP, Antman EM, Braunwald E, Gibson CM. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. <i>Am J Cardiol</i> 2003;92:913-8. PMID:14556865.
37.	Gibson CM, Karha J, Murphy SA, de Lemos JA , Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. <i>J Am Coll Cardiol</i> 2004;43:1170-6. PMID:15063425.
38.	Mayer SA, de Lemos JA , Murphy SA, Brooks S, Roberts BJ, Grayburn, PA. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. <i>Am J Cardiol</i> 2004; 93:1002-6. PMID:15081443.
39.	Wylie JV, Murphy SA, Morrow DA, de Lemos JA , Antman EM, Cannon CP. A Validated Risk Score Predicts the Development of Congestive Heart Failure After Presentation with Unstable Angina or Non-ST Elevation Myocardial Infarction: Results from OPUS-TIMI 16 and TACTICS-TIMI 18. <i>Am Heart J</i> 2004;148:173-80. PMID:15215808.
40.	Blazing MA, de Lemos JA , White HD, Fox KAA, Verheugt FWA, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, for the A to Z Investigators. Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin: A Randomized Controlled Trial. <i>JAMA</i> 2004;292:55-64. PMID:15238591.
41.	Petersen JL, Mahaffey KM, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA , Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview. <i>JAMA</i> 2004;292:89-96. PMID:15238596.
42.	Mega JL, Morrow DA, de Lemos JA , Sabatine MS, Murphy SA, Rifai N, Gibson CM, Antman EM, Braunwald E. BNP at presentation and prognosis in patients with ST-Elevation myocardial infarction: An ENTIRE-TIMI 23 Substudy. <i>J Am Coll Cardiol</i> 2004;44:335-9. PMID:15261928.
43.	Sadanandan S, Cannon CP, Kasi C, Murphy SA, Dibattiste P, Morrow DA, de Lemos JA , Braunwald E, Gibson CM. Association of Elevated B-type Natriuretic Peptide Levels with Angiographic Findings Among Patients with Unstable Angina and Non ST Elevation Myocardial Infarction. <i>J Am Coll Cardiol</i> 2004;44:564-8. PMID:15358021.
44.	de Lemos JA , Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial. <i>JAMA</i> . 2004 292:1307-16. PMID:15337732.
45.	de Lemos JA , Blazing MA, Wiviott SD, Brady WE, White HD, Fox KAA, Palmisano J, Ramsey KE, Bilheimer D, Lewis EF, Califf RM, Braunwald E. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A to Z trial. <i>Eur Heart J</i> 2004; 25:168894. PMID:15451146.

46.	Sallach SM, Nowak R, Hudson MP, Tokarski G, Khoury N, Tomlanovich MC, Jacobsen G, de Lemos JA , McCord J. A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels. <i>Am J Cardio</i> 2004;94:864-7. PMID:15464666.
47.	Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos JA , Ribeiro AL, Teixeira MM. Brain natriuretic peptide and left ventricular dysfunction in chagastic cardiomyopathy. <i>Mem Inst Oswaldo Cruz</i> 2004; 99:645-9. PMID:15558179.
48.	Addo T, Keeley EC, Cigarroa JE, Lange RA, de Lemos JA , Dobbins RL, McGuire DK. The Effect of Glucose-Insulin-Potassium Infusion on Plasma Free Fatty Acid Concentrations in the Setting of Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction. <i>Am J Cardiol.</i> 2004 Nov 15;94(10):1288-9. PMID:15541248.
49.	Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto J, Morrow DA, de Lemos JA . Association between plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors and subclinical atherosclerosis. <i>J Am Coll Cardiol</i> 2004;44:1812-8. PMID:15519012.
50.	Sabatine MA, Morrow DA, de Lemos JA , Omland T, Desai MY, Tanasijevic M, Hall C, McCabe CH, Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. <i>J Am Coll Cardiol</i> 2004; 44:1988-95. PMID:15542281.
51.	Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos JA , Ribiero AL, Teixeira MM. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. <i>Int J Cardiol</i> 2005;100:503-4. PMID:15837098.
52.	Sims JB, de Lemos JA , Maewal P, Warner JJ, Peterson GE, McGuire DK. Urinary Tract Infection in Patients with Acute Coronary Syndrome: A Potential Systemic Inflammatory Connection. <i>Am Heart J</i> 2005;149:1062-5. PMID:15976789.
53.	Khera A, McGuire DK, Murphy SA, Stanek G, Das S, Vongpatanasin W, Wians F, Grundy SM, de Lemos JA . Race and sex differences in C-reactive protein levels. <i>J Am Coll Cardiol</i> 2005; 46:464-9. PMID:16053959.
54.	Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA , Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E, for the FASTER (TIMI 24) Investigators. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. <i>Am Heart J.</i> 2005;150:79-88. PMID:16084152.
55.	Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH, de Lemos JA . Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results from the Dallas Heart Study. <i>Circulation</i> 2005; 112:2163-8. PMID:16203929.
56.	de Lemos JA , Zirlik A, Schönbeck U, Varo N, Murphy S, Khera A, McGuire DK, Stanek G, Lo H, Nuzzo R, Morrow DA, Peshock R, Libby P. Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study. <i>ATVB</i> 2005 25:2192-6. PMID:16109925.
57.	Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA . Relation of Coronary Atherosclerosis Determined by Electron Beam Computed Tomography and Plasma Levels of N-terminal Pro-Brain Natriuretic Peptide in a Multiethnic Population-Based Sample (The Dallas Heart Study). <i>Am J Cardiol</i> 2005; 96(9):1284-9. PMID:16253599.
58.	Morrow DA, de Lemos JA , Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KAA, Califf RM, Braunwald E. Prognostic Value of B-type Natriuretic Peptide During Followup of Patients with Unstable Coronary Artery Disease in the A to Z Trial. <i>JAMA</i> 2005; 294:2866-71. PMID:16352794.

59.	Robinson CR, Martin JL, Zhang L, Canham RM, Abdullah SM, Cigarroa JE, Hillis LD, Murphy SA, McGuire DK, de Lemos JA , Keeley EC. Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction. <i>Am J Cardiol</i> 2006; 97:7-9. PMID:16377273.
60.	Khera A, de Lemos JA , Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH, Grundy SM, McGuire DK. Relationship between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study. <i>Circulation</i> 2006; 113:38-43. PMID:16380546.
61.	Wiviott SD, de Lemos JA , Cannon CP, Blazing MA, Murphy SA, McCabe CH, Califf RM, Braunwald E. A Tale of Two Trials: A Comparison of the Post-ACS Lipid Lowering Trials A to Z and PROVE IT – TIMI 22. <i>Circulation</i> 2006; 21:1406-14. PMID:16534008.
62.	Wallace TW, Abdullah S, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatine MS, Morrow DA, de Lemos JA . Prevalence and Determinants of Troponin T Elevation in the General Population. <i>Circulation</i> 2006; 113:1958-65. PMID:16618821.
63.	Briel M, Schwartz GG, Thompson PL, de Lemos JA , Blazing MA, van Es G-A, Kayikcioglu M, Arntz H-R, den Hartog F, Veeger N, Colivicchi F, Dupuis J, Okazaki J, Wright S, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>JAMA</i> 2006;295:2046-2056. PMID:16670413.
64.	Das SR, Vaeth PA, Stanek HG, de Lemos JA , Dobbins RL, McGuire DK. Increased cardiovascular risk associated with diabetes in Dallas County. <i>Am Heart J</i> . 2006 May;151(5):1087-93. PMID:16644340.
65.	Morrow DA, de Lemos JA , Sabatine MS, Wiviott SD, Blazing MA, Hsui A, Rifai N, Ridker PM, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. <i>Circulation</i> 2006;114:281-8. PMID:16847150.
66.	O'Donoghue M, de Lemos JA , Morrow DA, Murphy SA, Buross JL, Cannon CP, Sabatine MS. Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. <i>Circulation</i> . 2006;114: 550–557. PMID:16880323.
67.	Kamath SA, Meo Neto J, Canham RM, Uddin F, Toto KH, Nelson LL, Kaiser PA, de Lemos JA , Drazner MH. Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction. <i>Am Heart J</i> 2006; 152:355-61. PMID:16875922.
68.	de Lemos JA , Wiviott SD, Murphy SA, Blazing MA, Lewis EF, Califf RM, Pfeffer MA, Braunwald E. Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: Insights from the A to Z trial. <i>Am J Cardiol</i> 2006; 98:739-42. PMID:16950174.
69.	Singh U, Otvos J, Dasgupta A, de Lemos JA , Devaraj S, Jialal I. High-Dose {alpha}Tocopherol Therapy Does Not Affect HDL Subfractions in Patients with Coronary Artery Disease on Statin Therapy. <i>Clin Chem</i> 2007; 53:525-8. PMID:17234730.
70.	Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ, de Lemos JA . Associations between androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. <i>J Am Coll Cardiol</i> 2007;49: 109-16. PMID:17207730.
71.	Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA . Relation of Osteoprotegerin to Coronary Calcium and Aortic Plaque (from the Dallas Heart Study). <i>Am J Cardiol</i> . 2007; 99(4):513-8. PMID:17293196.

72.	Abdullah SM, Khera A, Leonard D, Das SR, Canham RM, Kamath SA, Vega GL, Grundy SM, McGuire DK, de Lemos JA . Sex Differences in the Association between Leptin and CRP: Results from the Dallas Heart Study. <i>Atherosclerosis</i> 2007;195:404-10. PMID:17141244.
73.	Phillips B, de Lemos JA , Patel M, McGuire DK, Khera A. Relation of Family History of Myocardial Infarction and the Presence of Coronary Arterial Calcium in Various Age and RiskFactor Groups. <i>Am J Cardiol</i> 2007; 99:825-9. PMID:17350375.
74.	Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, de Lemos JA , Drazner MH. Left Ventricular Hypertrophy, Subclinical Atherosclerosis, and Inflammation. <i>Hypertension</i> 2007; 49:1385-91. PMID:17404181.
75.	Omland T,Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA . Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. <i>Hypertension</i> 2007; 49:1392-8. PMID:17470718.
76.	Parekh NK, Hynan LS, de Lemos JA , Lee WM. Elevated troponin I levels in acute liver failure: is myocardial injury an integral part of acute liver failure? <i>Hepatology</i> . 2007;45:1489-95. PMID:17538968.
77.	Jacobi JA, Parikh SV, McGuire DK, de Lemos JA , Murphy SA, Keeley EC. Racial disparity in clinical outcomes following primary percutaneous coronary intervention for ST elevation myocardial infarction: influence of process of care. <i>J Interv Cardiol</i> 2007;20:182-7. PMID:17524109.
78.	See R, Abdullah SM, McGuire DK, Khera A, MD, Patel MJ, Lindsey J, Grundy SM, de Lemos JA . The Association of Differing Measures of Overweight and Obesity with Prevalent Atherosclerosis: the Dallas Heart Study. <i>J Am Coll Cardiol</i> 2007;50:752-9. PMID:17707180.
79.	Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schönbeck U, Khera A, McGuire DK Vega PGL, Grundy S, Libby P, de Lemos JA . Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. <i>Arterioscler Thromb Vasc Biol</i> 2007 27:2043-9. PMID:17626902.
80.	Patel MJ, de Lemos JA , Philips B, Murphy SA, Vaeth PC, McGuire DK, Khera A. Implications of family history of myocardial infarction in young women. <i>Am Heart J</i> . 2007; 154:454-60. PMID:17719289.
81.	Scirica BM, Morrow DA, Cannon CP, de Lemos JA , Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. <i>Clin Chem</i> . 2007; 53:1800-7. PMID:17717132.
82.	Murphy SA, Cannon CP, Wiviott SD, de Lemos JA , Blazing MA, McCabe CH, Califf, RC, Braunwald E. Effect of intensive lipid lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the A to Z and PROVE IT TIMI 22 trials). <i>Am J Cardiol</i> 2007; 100:1047-51. PMID:17884359.
83.	Parikh SV, Abdullah SM, Keeley EC, Cigarroa JE, Addo TA, Warner JJ, Khera A, de Lemos JA , McGuire DK. Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK. <i>Diab Vasc Dis Res</i> . 2007; 4:222-5. PMID:17907112.
84.	Devaraj S, Tang R, Adams-Huet B, Harris A, Seenivasan T, de Lemos JA , Jialal I. Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. <i>Am J Clin Nutr</i> 2007;86:1392-8. PMID:17991651.
85.	de Lemos JA , Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E. Serial Measurement of Monocyte Chemoattractant Protein-1 Following Acute

	Coronary Syndromes: Results from the A to Z Trial. <i>J Am Coll Cardiol</i> 2007; 50:2117-24. PMID:18036447.
86.	Parikh SV, Jacobi JA, Chu E, Addo TA, Warner JJ, Delaney KA, McGuire DK, de Lemos JA , Cigarroa JE, Murphy SA, Keeley EC. Treatment delay in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a key process analysis of patient and program factors. <i>Am Heart J.</i> 2008;155:290-7. PMID:18215599.
87.	Baber U, de Lemos JA , Khera A, Omland T, McGuire DK, Toto RD, Hedayati SS. Nontraditional risk factors predict coronary calcification in chronic kidney disease in a populationbased cohort. <i>Kidney International</i> 2008; 73:615-21. PMID:18075501.
88.	Yorio J, Viswanathan S, See R, Uchal L, McWhorter J, Spencer N; Murphy S, Khera A, de Lemos JA ; McGuire DK. The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance: Results From the Parkland Acute Coronary Event Treatment Study. <i>J Investig Med.</i> 2008 Jan;56(1):15-25 PMID:18317424.
89.	Mielniczuk LM, Pfeiffer MA, Lewis EF, Blazing MA, de Lemos JA , Shui A, Mohanavelu S, Califf RM, Braunwald E. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. <i>Am Heart J.</i> 2008;155:725-31. PMID:18371483.
90.	Vale N, Nordmann AJ, Schwartz GG, de Lemos JA , Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills E, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. <i>Cochrane Database of Systematic Reviews</i> 2008, <i>Cochrane Database Syst Rev.</i> 2011 Jun 15;(6):CD006870. doi: 10.1002/14651858.CD006870.pub2. PMID:21678362.
91.	Purcell J Patel M, Khera A, de Lemos JA , Forbess LW, Baker S, Cabell CH, Peterson GE. Relation of troponin elevation to outcome in patients with infective endocarditis. <i>Am J Cardiol</i> 2008;101:1479-81. PMID:18471461.
92.	Chin KM, Kingman M, de Lemos JA , Warner JJ, Reimold S, Peshock R, Torres F. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. <i>Am J Cardiol.</i> 2008;101:166972. PMID:18489949.
93.	See R, Lindsey JB, Patel MJ, Ayers CR, Khera A, Grundy SM, McGuire DK, de Lemos JA . Application of the Screening for Heart Attack Prevention and Education (SHAPE) Guidelines to an Urban Population: Observations from the Dallas Heart Study. <i>Archives Int Med</i> 2008;168:1055-62. PMID:18504333.
94.	Mega JL, Morrow DA, de Lemos JA , Mohanavelu S, Cannon CP, Sabatine MS. Thrombus Precursor Protein (TpP) and Clinical Outcomes In Patients with Acute Coronary Syndromes. <i>J Am Coll Cardiol</i> 2008; 51:2422-9. PMID:18565400.
95.	Brilakis EM, Khera A, McGuire DK, Banerjee S, Murphy SA, de Lemos JA . Influence of Race and Sex on Lipoprotein-Associated Phospholipase A2 Levels: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> 2008;199:110-5. PMID:18061193.
96.	Chen K, Lindsey JB, Khera A, de Lemos JA , Ayers CR, Goyal A, Vega GL, Murphy SA, Grundy SM, McGuire DK. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. <i>Diabetes and Vascular Care</i> 2008; 5:96-101. PMID:18537096.
97.	Morrow DA, Sabatine MS, Brennan ML, de Lemos JA , Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. <i>Eur Heart J.</i> 2008; 29:1096-1102. PMID:18339606.
98.	Paiva MS, Serrano Jr CV, Nicolau JC, Jalbut BO, Fernandes JL, de Lemos JA , Blotta MH, DE Oliveira RT, DE Oliveira IR, DE Oliveira LD, Ramires JA. Differences in the Inflammatory

	Response between Patients with and Those without Diabetes Mellitus after Coronary Stenting. <i>J Interv Cardiol</i> 2008; 21:403-9. PMID:18705636.
99.	Chin K, Channick R, de Lemos JA , Kim N, Torres F, Rubin L. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. <i>Chest</i> 2009; 135:130-6. PMID:18719056.
100.	Matulevicius, S, Rohatgi, A, Khera, A, Das, SR, Owens, A, Ayers, C, Timaran, CH, Rosero, EB, Drazner, MH, Peshock, RM, de Lemos JA . The Association between Plasma Caspase-3, Atherosclerosis, and Vascular Function in the Dallas Heart Study. <i>Apoptosis</i> 2008;13:1281-9. PMID:18763039.
101.	Brilakis ES, de Lemos JA , Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of Patients With Acute Coronary Syndrome and Prior Coronary Artery Bypass Grafting (From the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE-IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). <i>Am J Cardiol</i> 2008 102(5):552-8. PMID:18721511.
102.	Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A, McGuire DK, de Lemos JA . Association Between Renal Function and Circulating Levels of Natriuretic Peptides (From the Dallas Heart Study). <i>Am J Cardiol</i> 2008;102:1394-8. PMID:18993162.
103.	Brilakis ES, Khera A, Saeed B, Banerjee S, Maguire DK, Murphy SA, de Lemos JA . Association of Lipoprotein-Associated Phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. <i>Clin Chem</i> 2008; 54(12):1975-81. PMID:18832472.
104.	Albert MA, Ravenell J, Glynn RJ, Khera A, Halevy N, de Lemos JA . Cardiovascular Risk Indicators and Perceived Race/Ethnic Discrimination in the Dallas Heart Study. <i>Am Heart J</i> 2008;156:1103-9. PMID:19033005.
105.	Rohatgi A, Ayers C, Khera A, McGuire DK, Das S, Matulevicius S, Timaran C, Rosero E, de Lemos JA . The Association Between Peptidoglycan Recognition Protein-1 and Coronary and Peripheral Atherosclerosis: Observations From the Dallas Heart Study. <i>Atherosclerosis</i> 2009; 203:569-75. PMID:18774573.
106.	Sabatine MS, Morrow DA, de Lemos JA , Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. <i>Eur Heart J</i> 2009; 30:162-9. PMID:18997177.
107.	Brilakis E, Lichtenwalter C, de Lemos JA , Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar baremetal stent in saphenous vein graft lesions: the SOS (Stenting of Saphenous Vein Grafts) trial. <i>J Am Coll Cardiol</i> 2009; 53:919-28. PMID:19281920.
108.	Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, de Lemos JA , Witztum JL. Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Results From the Dallas Heart Study. <i>Circulation</i> 2009; 119:1711-9. PMID:19307470.
109.	Serrano CV, Pesaro AE, de Lemos JA , Rached F, Segre CA, Gomes F, Ribeiro AF, Nicolau JC, Yoshida VM, Monteiro HP. Native LDL-cholesterol mediated monocyte adhesion molecule overexpression is blocked by simvastatin. <i>Cardiovascular Drugs and Therapy</i> 2009; 23:215-20. PMID:19125317.

110.	de Lemos JA , McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the Population for Left Ventricular Hypertrophy and Left Ventricular Systolic Dysfunction Using Natriuretic Peptides: Results from the Dallas Heart Study. <i>Am Heart J</i> 2009;157:746-753. PMID:19332205.
111.	Parikh S, Treichler B, DePaolo S, Sharpe J, Valdez M, Addo T, Das SR, McGuire DK, de Lemos JA , Keeley EC, Warner JJ, Holper E. Systems-Based Improvement in Door-to Balloon Times at a Large, Urban Teaching Hospital (A Follow-up Study from Parkland Health and Hospital Systems). <i>Circulation: Cardiovascular Quality and Outcomes</i> . 2009; 2:116-122. PMID:20031823.
112.	Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA , Balko JA, Gupta S, Mammen PP, Drazner MH, Markham DW. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. <i>Circ Heart Fail</i> . 2009; 2:98-104. PMID:19808324.
113.	Patel MJ, de Lemos JA , McGuire DK, See R, Lindsey JB, Murphy SA, Grundy SM, Khera A. Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study. <i>Am Heart J</i> 2009; 157:1001-9. PMID:19464410.
114.	Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA . Sex Differences in the Relationship Between C-Reactive Protein and Body Fat. <i>J Clin Endocrinol Metab</i> . 2009; 94:3251-8. PMID:19567538.
115.	Lindsey JB, de Lemos JA , Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK. Association Between Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and Risk for Atherosclerosis: Observations from the Dallas Heart Study. <i>Diabetes Care</i> 2009; 32(7):1218-20. PMID:19366975.
116.	Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, Berry JD, McGuire DK, de Lemos JA . Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. <i>Arterioscler Thromb Vasc Biol</i> . 2009;29:1684-90. PMID:19759376.
117.	Lichtenwalter C, de Lemos JA , Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. <i>JACC Cardiovasc Interv</i> 2009; 2:855-60. PMID:19778774.
118.	Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, de Lemos JA , Mohanavelu S, Rouleau J, Fox K, Pedersen TR, Califf RM. Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. <i>Clin J Am Soc Nephrol</i> .2009;4:1811-7. PMID:19820133.
119.	Omland T, de Lemos JA , Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E. A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease. <i>N Engl J Med</i> . 2009 361:2538-47. PMID:19940289.
120.	Khoury MG, Peshock RM, Ayers CR, de Lemos JA , Drazner MH. A Four-Tiered Classification of Left Ventricular Hypertrophy Based on Left Ventricular Geometry: The Dallas Heart Study. <i>Circ Cardiovasc Imaging</i> . 2010;3:164-71. PMID:20061518.

121.	Castillo L, Rohatgi A, Ayers CR, Owens AW, Das SR, Khera A, McGuire DK, de Lemos JA . Associations of Four Circulating Chemokines With Multiple Atherosclerosis Phenotypes in a Large Population-Based Sample: Results From the Dallas Heart Study. <i>J Interferon Cytokine Res.</i> 2010; 30:339-47. PMID:20187767.
122.	Morrow DA, Scirica BM, Sabatine MS, de Lemos JA , Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald E. B-type natriuretic peptide and the effect of ranolazine in patients with non-STsegment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. <i>J Am Coll Cardiol.</i> 2010 Mar 23;55(12):1189-96 PMID:20298924.
123.	Parikh SV, de Lemos JA , Jessen ME, Brilakis ES, Ohman EM, Chen AY, Wang TY, Peterson ED, Roe MT, Holper EM. Timing of in-hospital coronary artery bypass graft surgery for nonST-segment elevation myocardial infarction patients; results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). <i>JACC Cardiovasc Interv</i> 2010; 4:41927. PMID:20398870.
124.	Gupta S, Berry JD, Ayers CR, Peshock RM, Khera A, de Lemos JA , Patel PC, Markham DW, Drazner MH. Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease:the Dallas Heart Study. <i>JACC Cardiovasc Imaging</i> 2010; 3:605-13. PMID:20541716
125.	McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, Ayers CR, Drazner MH, Khera A, de Lemos JA . Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. <i>Eur Heart J.</i> 2010; 18:2262-70. PMID:20601395.
126.	Badhey N, Lichtenwalter C, de Lemos JA , Roesle M, Obel O, Addo TA, Haagen D, AbdelKarim AR, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. <i>Catheter Cardiovasc Interv.</i> 2010;76:263-9. PMID:20665875.
127.	Owens AW, Matulevicius S, Rohatgi A, Ayers CR, Das SR, Khera A, McGuire DK, de Lemos JA . Circulating lymphotoxin beta receptor and atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis.</i> 2010; 212:601-6. PMID:20599198.
128.	Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. <i>Lancet.</i> 2010; 376:1670-81.
129.	Shiue AB, Stancoven AB, Purcell JB, Pinkston K, Wang A, Khera A, de Lemos JA , Peterson GE. Relation of level of B-type natriuretic Peptide with outcomes in patients with infective endocarditis. <i>Am J Cardiol.</i> 2010;106:1011-5. PMID:20854966.
130.	Powell TM, de Lemos JA , Banks K, Ayers CR, Rohatgi A, Khera A, McGuire DK, Berry JD, Albert MA, Vega GL, Grundy SM, Das SR. Body size misperception: a novel determinant in the obesity epidemic. <i>Arch Intern Med.</i> 2010;170:1695-7. PMID:20937931.

131.	Kontos MC, de Lemos JA , Ou FS, Wiviott SD, Foody JM, Newby LK, Chen A, Roe MT. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. <i>Am Heart J.</i> 2010;160(5):819-25. PMID:21095267.
132.	Chang AY, Ayers C, Minhajuddin A, Jain T, Nurenberg P, de Lemos JA , Wild RA, Auchus RJ. Polycystic Ovarian Syndrome and Subclinical Atherosclerosis Among Women of Reproductive Age in the Dallas Heart Study. <i>Clin Endocrinol (Oxf).</i> 2011 Jan;74(1):89-96 PMID:21044112.
133.	deFilippi CR, de Lemos JA , Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older Adults. <i>JAMA</i> 2010; 304:2494-502. PMID:21078811.
134.	de Lemos JA , Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of Troponin T Detected Using a Highly Sensitive Assay With Cardiac Structure and Mortality Risk in the General Population. <i>JAMA</i> 2010; 304:2503-12. PMID:21139111.
135.	Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. <i>Lancet.</i> 2010; 376:1670-81. PMID:21067804.
136.	Banks K, Puttagunta D, Murphy SA, Lo M, McGuire SK, de Lemos JA , Chang, AY, Grundy SM, Khera A. Clinical Characteristics, Vascular Function, and Inflammation in Women with Angina in the Absence of Coronary Atherosclerosis: The Dallas Heart Study. <i>JACC Cardiovascular Imaging</i> 2011; 4:65-73. PMID:21232706.
137.	Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, Tortorice KL, Shank M, Cryer B, Reilly RF, Rao SV, Kastrati A, de Lemos JA , Brilakis ES, Bhatt DL. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. <i>Am J Cardiol</i> 2011;107:871-8. PMID:21247527.
138.	Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JA , Braunwald E, Morrow DA. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. <i>Eur Heart J</i> 2011; 32:697-705. PMID:21183500.
139.	Brilakis ES, Lichtenwalter C, Abdel-Karim AR, de Lemos JA , Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued Benefit From Paclitaxel-Eluting Compared With Bare-Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting of Saphenous Vein Grafts) Trial. <i>JACC Cardiovasc Interv.</i> 2011; 4:176-82. PMID:21349456.
140.	Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, Drazner MH, de Lemos JA , Berry JD. Cardiorespiratory Fitness and Classification of Risk of Cardiovascular Disease Mortality. <i>Circulation.</i> 2011; 123:1377-83. PMID:21422392.

141.	Saunders JT, Nambi V, de Lemos JA , Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study. <i>Circulation</i> 2011; 13:1367-76. PMID:21422391.
142.	Berry JD, Willis B, Gupta S, Barlow CE, Lakoski SG, Khera A, Rohatgi A, de Lemos JA , Haskell W, Lloyd-Jones DM. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men the Cooper Center Longitudinal study. <i>J Am Coll Cardiol</i> 2011; 57:1604-10. PMID:21474041.
143.	Gupta S, Rohatgi A, Ayers CR, Patel PC, Matulevicius SA, Peshock RM, Markham DW, de Lemos JA , Berry JD, Drazner MH. Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure. <i>Am Heart J</i> . 2011; 161:923-930. PMID:21570524.
144.	Narang N, Armstead SI, Stream A, Abdullah SM, See R, Snell PG, McGavock J, Ayers CR, Gore MO, Khera A, de Lemos JA , McGuire DK. Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. <i>Diab Vasc Dis Res</i> . 2011; 8:101-8. PMID:21562061.
145.	Stancoven AB, Shiue AB, Khera A, Pinkston K, Hashim IA, Wang A, de Lemos JA , Peterson GE. Association of Troponin T, Detected With Highly Sensitive Assay, and Outcomes in Infective Endocarditis. <i>Am J Cardiol</i> . 2011; 108:416-20. PMID:21600535.
146.	Turer AT, Addo TA, Martin JL, Sabatine MS, Lewis GD, Gerszten RE, Keeley EC, Cigarroa JE, Lange RA, Hillis LD, de Lemos JA . Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. <i>J Am Coll Cardiol</i> . 2011 Jun 14;57(24):2398-405. PMID:21658559.
147.	Wilson SR, Sabatine MS, Wiviott SD, Ray KK, de Lemos JA , Zhou S, Rifai N, Cannon CP, Morrow DA. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). <i>Am Heart J</i> 2011; 161:1147-1155. PMID:21641362.
148.	Michael TT, Abdel-Karim AR, Papayannis A, Lichtenwalter C, de Lemos JA , Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES. Recurrent Cardiovascular Events with Paclitaxel-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Lesions: Insights from the SOS (Stenting of Saphenous Vein Grafts) Trial. <i>J Invasive Cardiol</i> 2011; 23:216-9. PMID:21646644.
149.	Vale N, Nordmann AJ, Schwartz GG, de Lemos JA , Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills E, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. <i>Cochrane Database Syst Rev</i> . 2011 Jun 15;(6):CD006870. PMID:21678362.
150.	Preiss D, Rao S, Seshasai D, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JD, de Lemos JA , Blazing MA, Pedersen TF, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. <i>JAMA</i> 2011;305:2556-64. PMID:21693744.
151.	Williams RS, de Lemos JA , Dimas V, Reisch J, Hill JA, Naseem RH. Effect of spironolactone on patients with atrial fibrillation and structural heart disease. <i>Clin Cardiol</i> 2011; 34:415-9. PMID:21674535.

152.	Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, Lakoski SG, Berry JD, Khera A, McGuire DK, de Lemos JA . Interactions Between Smoking, Pulmonary Surfactant Protein B, and Atherosclerosis in the General Population: The Dallas Heart Study. <i>Arterioscler Thromb Vasc Biol.</i> 2011;31:2136-43. PMID:21817103.
153.	DeHaven MJ, Ramos-Roman MA, Gimpel N, Carson J, de Lemos JA , Pickens S, Simmons C, Powell-Wiley T, Banks-Richard K, Shuval K, Duval J, Tong L, Hsieh N, Lee JJ. The GoodNEWS (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial: a communitybased participatory research (CBPR) trial with African-American church congregations for reducing cardiovascular disease risk factors--recruitment, measurement, and randomization. <i>Contemp Clin Trials</i> 2011;32:630-40. PMID:21664298.
154.	Chen LQ, Rohatgi A, Ayers CR, Das SR, Khera A, Berry JD, McGuire DK, de Lemos JA . Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: The Dallas Heart Study. <i>Atherosclerosis</i> 2011; 219:833-8. PMID:21917261.
155.	Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA , Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. <i>JAMA</i> 2011; 306:864-71. PMID:21862748.
156.	Grodin JL, Powell-Wiley TM, Ayers CR, Kumar DS, Rohatgi A, Khera A, McGuire DK, de Lemos JA , Das SR. Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: From the Dallas Heart Study. <i>Vasc Med</i> 2011;16:339-45. PMID:22002999
157.	Jeroudi OM, Abdel-Karim AR, Michael TT, Lichtenwalter C, de Lemos JA , Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Raghunathan D, Dasilva M, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. <i>EuroIntervention</i> 2011; 7:948-54. PMID:22157480.
158.	Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, Roe MT, de Lemos JA . Impact of Body Weight and Extreme Obesity on the Presentation, Treatment, and In-Hospital Outcomes of 50,149 Patients With ST-Segment Elevation Myocardial Infarction Results From the NCDR (National Cardiovascular Data Registry). <i>J Am Coll Cardiol</i> 2011; 58:2642-2650. PMID:22152950.
159.	Pesaro AE, Serrano CV Jr, Fernandes JL, Cavalcanti AB, Campos AH, Martins HS, Maranhão RC, de Lemos JA , Souza HP, Nicolau JC. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. <i>Int J Cardiol.</i> 2012 Jul 26;158(3):400-4. PMID:21334753.
160.	Narang N, Gore MO, Snell PG, Ayers CR, Lorenzo S, Carrick-Ranson G, Babb TG, Levine BD, Khera A, de Lemos JA , McGuire DK. Accuracy of Estimating Resting Oxygen Uptake and Implications for Hemodynamic Assessment. <i>Am J Cardiol</i> 2012; 109:594-8. PMID:22100029.
161.	Briel M, Vale N, Schwartz GG, de Lemos JA , Colivicchi F, den Hartog FR, Ostadal P, Macin SM, Liem A, Mills E, Bhatnagar N, Bucher HC, Nordmann AJ. Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients. <i>Int J Cardiol.</i> 2012; 158:93-100. PMID:21295870.
162.	McGavock J, Szczepaniak LS, Ayers CR, Abdullah SM, See R, Gore MO, Drazner MH, de Lemos JA , McGuire DK. The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial. <i>Diab Vasc Dis Res</i> 2012; 9:131-7. PMID:22067724.

163.	Rohatgi A, Patel P, Das SR, Ayers CR, Khera A, Martinez-Rumayor A, Berry JD, McGuire DK, de Lemos JA . Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multi-ethnic Population: Observations from the Dallas Heart Study. <i>Clin Chem</i> 2012;58:172-82. PMID:22065155.
164.	Sabatine MS, Morrow DA, de Lemos JA , Omland T, Sloan S, Jarolim P, Solomon S, Pfeffer MA, Braunwald E. Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease. <i>Circulation</i> 2012; 125:233-40. PMID:22179538.
165.	Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. <i>PLoS One</i> . 2012;7:e29849.
166.	Powell-Wiley TM, Ayers CR, Richard KB, Berry JD, Khera A, Lakoski SG, McGuire DK, de Lemos JA , Das SR. Disparities in Counseling for Lifestyle Modification Among Obese Adults: Insights from the Dallas Heart Study. <i>Obesity (Silver Spring)</i> . 2012; 20:849-55. PMID:21818156.
167.	Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. <i>PLoS One</i> . 2012;7(1):e29849. PMID:22276132.
168.	Neeland IJ, Sulistio MS, Stoller DA, de Lemos JA , Atkins JM, McGuire DK. Electrocardiographic patterns of proximal left anterior descending artery occlusion in STElevation myocardial infarction may be modified by 3-vessel coronary artery disease. <i>J Electrocardiol</i> . 2012;45:272-6. PMID:22244932.
169.	Chin CT, Wang TY, Li S, Wiviott SD, de Lemos JA , Kontos MC, Peterson ED, Roe MT. Comparison of the Prognostic Value of Peak Creatine Kinase-MB and Troponin Levels Among Patients With Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. <i>Clin Cardiol</i> . 2012; 35:4249. PMID:22434769.
170.	Dyer AK, Barnes AP, Fixler DE, Shah TK, Sutcliffe DL, Hashim I, Drazner MH, de Lemos JA . Use of a highly sensitive assay for cardiac troponin T and N-terminal pro-brain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients. <i>Am Heart J</i> . 2012; 163:595-600. PMID:22520525.
171.	Leonardi S, Chen AY, Gharacholou SM, Wang TY, de Lemos JA , Saucedo JF, Peterson ED, Roe MT. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. <i>Am Heart J</i> . 2012;164:502-8. PMID:23067907.
172.	Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet</i> . 2012; 380:581-90.
173.	Gupta NK, de Lemos JA , Ayers CR, Abdullah A, McGuire DK, Khera A. The relationship between c-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. <i>J Am Coll Cardiol</i> 2012; 60:1148-55. PMID:22939555.
174.	Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA . Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. <i>JAMA</i> . 2012; 308:1150-9. PMID:22990274.

175.	Gore MO, Patel MJ, Kosiborod M, Parsons LS, Khera A, de Lemos JA , Rogers WJ, Peterson ED, Canto JC, McGuire DK; for the National Registry of Myocardial Infarction Investigators. Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006: Data From the National Registry of Myocardial Infarction. <i>Circ Cardiovasc Qual Outcomes</i> . 2012; 5:791-7. PMID:23132330.
176.	Chen LQ, de Lemos JA , Das SR, Ayers CR, Rohatgi A. Soluble ST2 Is Associated with AllCause and Cardiovascular Mortality in a Population-Based Cohort: The Dallas Heart Study. <i>Clin Chem</i> . 2013;59:536-46. PMID:23220272.
177.	Defilippi CR, de Lemos JA , Tkaczuk AT, Christenson RH, Carnethon MR, Siscovick DS, Gottdiener JS, Seliger SL. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. <i>J Am Coll Cardiol</i> . 2012; 60:2539-47. PMID:23158528.
178.	Powell-Wiley TM, Banks-Richard K, Williams-King E, Tong L, Ayers CR, de Lemos JA , Gimpel N, Lee JJ, Dehaven MJ. Churches as targets for cardiovascular disease prevention: comparison of genes, nutrition, exercise, wellness and spiritual growth (GoodNEWS) and Dallas County populations. <i>J Public Health (Oxf)</i> . 2013;:35:99-106 PMID:22811446.
179.	Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, Levine BD, Chin KM, de Lemos JA , Peshock RM, Drazner MH. Left atrial structure and function and clinical outcomes in the general population. <i>Eur Heart J</i> . 2013;34:278-85. PMID:22782941.
180.	Neeland IJ, Drazner MH, Berry JD, Ayers CR, Defilippi C, Seliger SL, Nambi V, McGuire DK, Omland T, de Lemos JA . Biomarkers of chronic cardiac injury and hemodynamic stress
	identify a malignant phenotype of left ventricular hypertrophy in the general population. <i>J Am Coll Cardiol</i> . 2013; 61:187-95. PMID:23219305.
181.	Martinez-Rumayor AA, de Lemos JA , Rohatgi AK, Ayers CR, Powell-Wiley TM, Lakoski SG, Berry JD, Khera A, Das SR. Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic Peptide to electrocardiography for detection of left ventricular hypertrophy: results from the dallas heart study. <i>Hypertension</i> . 2013; 61:105-11. PMID:23150502.
182.	Enriquez JR, de Lemos JA , Parikh SV, Peng SA, Spertus JA, Holper EM, Roe MT, Rohatgi A, Das SR. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. <i>Am Heart J</i> . 2013;165:43-9. PMID:23237132.
183.	Gankam-Kengne F, Ayers C, Khera A, de Lemos JA , Maalouf NM. Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. <i>Kidney Int</i> . 2013; 83:700-6. PMID:23325088.
184.	Lo MY, Bonthala N, Holper EM, Banks K, Murphy SA, McGuire DK, de Lemos JA , Khera A. A Risk Score for Predicting Coronary Artery Disease in Women With Angina Pectoris and Abnormal Stress Test Finding. <i>Am J Cardiol</i> . 2013; 111(6):781-5. PMID:23273531.
185.	Omland T, Pfeffer MA, Solomon SD, de Lemos JA , Røsjø H, Saltytė Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E; PEACE Investigators. Prognostic Value of Cardiac Troponin I Measured With a Highly Sensitive Assay in Patients With Stable Coronary Artery Disease. <i>J Am Coll Cardiol</i> . 2013; 61(12):1240-9. PMID:23414791.
186.	Powell-Wiley TM, Ayers CR, de Lemos JA , Lakoski SG, Vega GL, Grundy S, Das SR, BanksRichard K, Albert MA. Relationship between perceptions about neighborhood environment and prevalent obesity: Data from the Dallas heart study. <i>Obesity (Silver Spring)</i> . 2013;21:E14-21. PMID:23404728.

187.	Gada E, Owens AW, Gore MO, See R, Abdullah SM, Ayers CR, Rohatgi A, Khera A, de Lemos JA , McGuire DK. Discordant effects of rosiglitazone on novel inflammatory biomarkers. <i>Am Heart J</i> 2013;165:609-14. PMID:23537979.
188.	Vélez-Martínez M, Ayers C, Mishkin JD, Bartolome SB, García CK, Torres F, Drazner MH, de Lemos JA , Turer AT, Chin KM. Association of Cardiac Troponin I With Disease Severity and Outcomes in Patients With Pulmonary Hypertension. <i>Am J Cardiol.</i> 2013; 111:1812-7. PMID:23540547.
189.	Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, Khera A, McGuire DK, Vega GL, de Lemos JA , Turer AT. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. <i>J Am Coll Cardiol.</i> 2013 Aug 20;62(8):752-60. PMID:23602771.
190.	Brayton KM, Patel VG, Stave C, de Lemos JA , Kumbhani DJ. Same-Day Discharge After Percutaneous Coronary Intervention: A Meta-Analysis. <i>J Am Coll Cardiol.</i> 2013; 62:752-60. PMID:23602771.
191.	Scirica BM, Kadakia MB, de Lemos JA , Roe MT, Morrow DA, Li S, Wiviott SD, Kontos MC; on behalf of the National Cardiovascular Data Registry. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry(R)-GWTG™. <i>Clin Chem.</i> 2013; 59:1205-14. PMID:23630179.
192.	Diercks DB, Kontos MC, Hollander JE, Mumma BE, Holmes DN, Wiviott S, Saucedo JF, de Lemos JA . ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. <i>Am J Emerg Med.</i> 2013; 31:1005-11. PMID:23702070.
193.	Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A, McGuire DK, Vega GL, Grundy SM, de Lemos JA , Drazner MH. Relation of regional fat distribution to left ventricular structure and function. <i>Circ Cardiovasc Imaging.</i> 2013; 6:800-7. PMID:23929898
194.	Neeland, IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA . Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. <i>Obesity</i> 2013; 21:439447.
195.	Rao KK, Enriquez JR, de Lemos JA , Alexander KP, Chen AY, McGuire DK, Fonarow GC, Das SR. Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). <i>Am Heart J.</i> 2013 Oct;166(4):709-15. PMID:24093851.
196.	Abdel-Karim AR, Da Silva M, Lichtenwalter C, de Lemos JA , Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Makke L, Jeroudi OM, Raghunathan D, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Prevalence and outcomes of intermediate saphenous vein graft lesions: Findings from the stenting of saphenous vein grafts randomized-controlled trial. <i>Int J Cardiol.</i> 2013;168:2468-73. PMID:23561918.
197.	Nambi V, Liu X, Chambless LE, de Lemos JA , Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, Srinivas PR, Deswal A, Mosley TH, Coresh J, Folsom AR, Heiss G, Ballantyne CM. Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk: The Atherosclerosis Risk in Communities Study. <i>Clin Chem.</i> 2013; 59:1802-10. PMID:24036936.

198.	Masoudi FA, Ponirakis A, Yeh RW, Maddox TM, Beachy J, Casale PN, Curtis JP, de Lemos JA , Fonarow G, Heidenreich P, Koutras C, Kremers M, Messenger J, Moussa I, Oetgen WJ, Roe MT, Rosenfield K, Shields TS, Spertus JA, Wei J, White C, Young CH, Rumsfeld JS. Cardiovascular Care Facts: A Report from the National Cardiovascular Data Registry - 2011. <i>J Am Coll Cardiol.</i> 2013; 33:1931-47. PMID:24036027.
199.	Gore MO, Lüneburg N, Schwedhelm E, Ayers CR, Anderssohn M, Khera A, Atzler D, de Lemos JA , Grant PJ, McGuire DK, Böger RH. Symmetrical Dimethylarginine Predicts Mortality in the General Population: Observations From the Dallas Heart Study. <i>Arterioscler Thromb Vasc Biol.</i> 2013; 33:2682-8. PMID:24008162.
200.	Narang N, Thibodeau JT, Levine BD, Gore MO, Ayers CR, Lange RA, Cigarroa JE, Turer AT, de Lemos JA , McGuire DK. Inaccuracy of Estimated Resting Oxygen Uptake in the Clinical Setting. <i>Circulation</i> 2014;129:203-10. PMID:24077170.
201.	Xing FY, Neeland IJ, Gore MO, Ayers CR, Paixao AR, Turer AT, Berry JD, Khera A, de Lemos JA , McGuire DK. Association of prediabetes by fasting glucose and/or haemoglobin A1c levels with subclinical atherosclerosis and impaired renal function: Observations from the Dallas Heart Study. <i>Diab Vasc Dis Res</i> 2014;1:11-8. PMID:24344119.
202.	Shavelle DM, Chen AY, Matthews RV, Roe MT, de Lemos JA , Jollis J, Thomas JL, French WJ. Predictors of Reperfusion Delay in Patients With ST Elevation Myocardial Infarction SelfTransported to the Hospital (from the American Heart Association's Mission: Lifeline Program). <i>Am J Cardiol.</i> 2014;113:798-802. PMID:24393257.
203.	Gupta N, Washam JB, Mountantonakis SE, Li S, Roe MT, de Lemos JA , Arora R. Characteristics, Management, and Outcomes of Cocaine-Positive Patients With Acute Coronary Syndrome (from the National Cardiovascular Data Registry). <i>Am J Cardiol</i> 2014; 113:749-56. PMID:24388623.
204.	Gore MO, Eason SJ, Ayers CR, Turer A, Khera A, de Lemos JA , McGuire DK, Sayers M. Glycated hemoglobin in 14,850 adolescent blood donors: a pilot screening program. <i>Diabetes Care.</i> 2014; 37:e3-4. PMID:24356607.
205.	Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA . Age and Sex Dependent Upper Reference Limits for the High Sensitivity Cardiac Troponin T Assay. <i>J Am Coll Cardiol.</i> 2014; 63:1441-8. PMID:24530665.
206.	Patel PC, Hill DA, Ayers CR, Kaiser P, Lavingia B, Dyer AK, Barnes AP, Thibodeau JT, Mishkin JD, Mammen PP, Markham DW, Stastny P, Ring WS, de Lemos JA , Drazner MH. High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant. <i>Circ Heart Failure</i> 2014;7:463-9. PMID:24733367.
207.	Sherwood MW, Wiviott SD, Peng SA, Roe MT, de Lemos JA , Peterson ED, Wang TY. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: Insights from the National Cardiovascular Data Registry. <i>J Am Heart Assoc</i> 2014;3:e000849. PMID:24732921.
208.	Petr EJ, Ayers CR, Pandey A, de Lemos JA , Powell-Wiley TM, Khera A, Lloyd-Jones DM, Berry JD. Perceived Lifetime Risk for Cardiovascular Disease (from the Dallas Heart Study). <i>Am J Cardiol</i> 2014;114:53-8. PMID:24834788.
209.	Sarma A, Cannon CP, de Lemos JA , Rouleau JL, Lewis EF, Guo J, Mega JL, Sabatine MS, O'Donoghue ML. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. <i>J Am Heart Assoc</i> 2014;3:e000784. PMID:24786143.

210.	Turer AT, Lewis GD, O'Sullivan JF, Elmariah S, Mega JL, Addo TA, Sabatine MS, de Lemos JA , Gerszten RE. Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. <i>PLoS One</i> 2014;9:e99058. PMID:24932507.
211.	Khalili H, Patel VG, Mayo HG, de Lemos JA , Brilakis E, Banerjee S, Bavry AA, Bhatt DL, Kumbhani DJ. Surrogate and clinical outcomes following ischemic postconditioning during primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a meta-analysis of 15 randomized trials. <i>Catheter Cardiovasc Interv</i> 2014; 84:978-86. PMID:24948465.
212.	Paixao AR, Berry JD, Neeland IJ, Ayers CR, Rohatgi A, de Lemos JA , Khera A. Coronary Artery Calcification and Family History of Myocardial Infarction in the Dallas Heart Study. <i>JACC Cardiovasc Imaging</i> 2014; 7:679-86. PMID:24954461.
213.	Brinker SK, Pandey A, Ayers CR, Barlow CE, DeFina LF, Willis BL, Radford NB, FarzanehFar R, de Lemos JA , Drazner MH, Berry JD. Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the cooper center longitudinal study. <i>JACC Heart Fail</i> 2014;2:238-46. PMID:24952690.
214.	Kulinski JP, Khera A, Ayers CR, Das SR, de Lemos JA , Blair SN, Berry JD. Association Between Cardiorespiratory Fitness and Accelerometer-Derived Physical Activity and Sedentary Time in the General Population. <i>Mayo Clin Proc</i> 2014; 89:1063-71. PMID:25012770.
215.	Wickramasinghe CD, Ayers CR, Das S, de Lemos JA , Willis BL, Berry JD. Prediction of 30year risk for cardiovascular mortality by fitness and risk factor levels: the cooper center longitudinal study. <i>Circ Cardiovasc Qual Outcomes</i> . 2014; 7:597-602. PMID:24987054.
216.	Udell JA, Wang TY, Li S, Kohli P, Roe MT, de Lemos JA , Wiviott SD. Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. <i>JAMA</i> . 2014; 312:841-843. PMID:25157729.
217.	Hall HM, de Lemos JA , Enriquez JR, McGuire DK, Peng SA, Alexander KP, Roe MT, Desai N, Wiviott SD, Das SR. Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results From the National Cardiovascular Data Registry (NCDR). <i>Circ Cardiovasc Qual Outcomes</i> 2014; 7:701-7. PMID:25116897.
218.	Khalili H, Edwards A, Jones J, de Lemos JA , Das SR. Rates of aldosterone antagonist use after myocardial infarction remain poor over time among guideline eligible patients. <i>Int J Cardiol</i> . 2014;176:1334-5 PMID:25115258.
219.	Atzler D, Gore MO, Ayers CR, Choe CU, Böger RH, de Lemos JA , McGuire DK, Schwedhelm E. Homoarginine and Cardiovascular Outcome in the Population-Based Dallas Heart Study. <i>Arterioscler Thromb Vasc Biol</i> 2014;34:2501-7. PMID:25189571.
220.	Paixao AR, Ayers CR, Berry JD, de Lemos JA , Khera A. Atherosclerotic Cardiovascular Disease Prevention: A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines. <i>Circ Cardiovasc Qual Outcomes</i> 2014; 7:7789. PMID:25097213.
221.	Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, Khera A, McGuire DK, de Lemos JA , Turer AT. The relationship of body mass and fat distribution with incident hypertension: observations from the dallas heart study. <i>J Am Coll Cardiol</i> . 2014; 64:997-1002. PMID:25190234.
222.	Vale N, Nordmann AJ, Schwartz GG, de Lemos JA , Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. <i>Cochrane Database Syst Rev</i> 2014 Sep 1;9:CD006870 PMID:25178118.

223.	Paixao AR, Ayers CR, Rohatgi A, Das SR, de Lemos JA , Khera A, Lloyd-Jones D, Berry JD. Cardiovascular lifetime risk predicts incidence of coronary calcification in individuals with low short-term risk: the Dallas Heart Study. <i>J Am Heart Assoc.</i> 2014;3(6):e001280. PMID:25424574.
224.	Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA , Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. <i>N Engl J Med.</i> 2014; 371:2383-93. PMID:25404125.
225.	Pokharel Y, Sun W, de Lemos JA , Taffet GE, Virani SS, Ndumele CE, Mosley TH, Hoogeveen RC, Coresh J, Wright JD, Heiss G, Boerwinkle EA, Bozkurt B, Solomon SD, Ballantyne CM, Nambi V. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. <i>Hypertension</i> 2015; 65:78-84. PMID:25350984.
226.	Omland T, de Lemos JA , Holmen OL, Dalen H, Benth JS, Nygård S, Hveem K, Røsjø H. Impact of Sex on the Prognostic Value of High-Sensitivity Cardiac Troponin I in the General Population: The HUNT Study. <i>Clin Chem.</i> 2015; 61:646-56. PMID: 25695851.
227.	Sanghavi M, Kulinski J, Ayers CR, Nelson D, Stewart R, Parikh N, de Lemos JA , Khera A. Association between number of live births and markers of subclinical atherosclerosis: The Dallas Heart Study. <i>Eur J Prev Cardiol.</i> 2015; 23:391-9. PMID: 25691547.
228.	Pandey A, Patel M, Gao A, Willis BL, Das SR, Leonard D, Drazner MH, de Lemos JA , DeFina L, Berry JD. Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The Cooper Center Longitudinal Study. <i>Am Heart J.</i> 2015;169:290-297 PMID: 25641539.
229.	Kulinski JP, Sanghavi M, Ayers CR, Das SR, Banerjee S, Berry JD, Addo T, de Lemos JA , Kumbhani DJ. Association between lo ankle-brachial index and accelerometer-derived sedentary and exercise time in the asymptomatic general population. <i>Vasc Med</i> 2015; 20:322-8. PMID 25883159.
230.	Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. <i>Lancet.</i> 2015;385:1397-405.
231.	Sosa A, Chao H, Guerra A, Han H, Christopoulos G, Christakopoulos GE, Tarar MN, de Lemos JA , Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Banerjee S, Brilakis ES.

	Paclitaxel-eluting vs bare metal stent implantation in saphenous vein graft lesions: Very longterm follow up of the SOS (Stenting of Sapphenuos vein grafts) trial. <i>Int J Cardiol</i> 2015;186:261-3. PMID: 25828130.
232.	Hess CN, Peterson ED, Peng SA, de Lemos JA , Fosbol EL, Thomas L, Bhatt DL, Saucedo JF, Wang TY. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. <i>J Am Coll Cardiol.</i> 2015;66:616-27. PMID: 26248987.
233.	Beg MS, Saleem S, Turer A, Ayers C, de Lemos JA , Khera A, Scherer PE, Lakoski SG. A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study. <i>J Natl Compr Canc Netw.</i> 2015;13:873-8 PMID: 26150581.
234.	Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA , Al-Khatib SM, Peterson ED, Wang TY. Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. <i>JAMA.</i> 2015;313:2433-40. PMID: 26103027.

235.	Paixao AR, Enriquez JR, Wang TY, Li S, Berry JD, Khera A, Das SR, de Lemos JA , Kontos MC. Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. <i>Am Heart J.</i> 2015;170:173-9. PMID: 26093879.
236.	Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, de Lemos JA . Antinuclear Antibodies Are Associated With All-Cause Mortality and Cardiovascular Outcomes in the General Population. <i>J Am Coll Cardiol.</i> 2015; 65:2669-70 PMID: 26088310.
237.	Gupta DK, de Lemos JA , Ayers CR, Berry JD, Wang TJ. Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. <i>JACC Heart Fail.</i> 2015;3:513-9. PMID: 26071618.
238.	Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>N Engl J Med.</i> 2015;372:2387-97. PMID: 26039521.
239.	Seliger SL, de Lemos J , Neeland IJ, Christenson R, Gottdiener J, Drazner MH, Berry J, Sorkin J, deFilippi C. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study). <i>JACC Heart Fail.</i> 2015;3:445-55 PMID: 25982111.
240.	Neeland IJ, Turer AT, Ayers CR, Berry JD, Rohatgi A, Das SR, Khera A, Vega GL, McGuire DK, Grundy SM, de Lemos JA . Body fat distribution and incident cardiovascular disease in obese adults. <i>J Am Coll Cardiol.</i> 2015; 65:2150-1 PMID: 25975481.
241.	Gore MO, Eason SJ, Ayers CR, Turer AT, Khera A, de Lemos JA , McGuire DK, Sayers M. High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents. <i>Diab Vasc Dis Res.</i> 2015;12:2728. PMID: 25972340.
242.	Garg S, de Lemos JA , Ayers C, Khouri MG, Pandey A, Berry JD, Peshock RM, Drazner MH. Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population. <i>JACC Cardiovasc Imaging.</i> 2015; 8:1034-41. PMID: 26298074.
243.	Raja V, Wiegand P, Obel O, Christakopoulos G, Christopoulos G, Rangan BV, Roesle M, Abdullah SM, Luna M, Addo T, Ayers C, Garcia S, de Lemos JA , Banerjee S, Brilakis ES. Impact of Chronic Total Occlusions and Coronary Revascularization on All-Cause Mortality and the Incidence of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. <i>Am J Cardiol.</i> 2015; 116:1358-62. PMID: 26341182.
244.	Kotsia AP, Rangan BV, Christopoulos G, Coleman A, Roesle M, Cipher D, de Lemos JA , McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. <i>J Invasive Cardiol.</i> 2015;27:E204-10. PMID: 26429851.
245.	Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de Lemos JA , Berry JD. Dose-Response Relationship Between Physical Activity and Risk of Heart Failure: A Meta-Analysis. <i>Circulation.</i> 2015; 132:1786-94. PMID: 26438781.
246.	Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, Amin A, Berry JD, Marwick TH, Marso SP, de Lemos JA , Kumbhani DJ. Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. <i>J Am Heart Assoc.</i> 2015; 4(10):e002137. PMID: 26459931.

247.	Paixao AR, Ayers CR, El Sabbagh A, Sanghavi M, Berry JD, Rohatgi A, Kumbhani DJ, McGuire DK, Das SR, de Lemos JA , Khera A. Coronary Artery Calcium Improves Risk Classification in Younger Populations. <i>JACC Cardiovasc Imaging</i> . 2015; 8:1285-93.PMID: 26476504.
248.	Enriquez JR, de Lemos JA , Parikh SV, Simon DN, Thomas LE, Wang TY, Chan PS, Spertus JA, Das SR. Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes: Results From the National Cardiovascular Data Registry. <i>Circ Cardiovasc Qual Outcomes</i> . 2015; 8:576-85. PMID: 26487739.
249.	Goyal A, de Lemos JA , Peng SA, Thomas L, Amsterdam EA, Hockenberry JM, Peterson ED, Wang TY. Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. <i>Circ Cardiovasc Qual Outcomes</i> . 2015;8:567-75. PMID: 26508667.
250.	Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA , Khera A, Kaplan N, Victor R, Vongpatanasin W. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study. <i>J Am Coll Cardiol</i> . 2015; 66:2159-69. PMID: 26564592.
251.	Guerra A, Rangan BV, Coleman A, Xu H, Kotsia A, Christopoulos G, Sosa A, Chao H, Han H, Abdurrahim G, Roesle M, de Lemos JA , McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINESVG) Pilot Trial. <i>J Invasive Cardiol</i> . 2015; 12:555-60. PMID: 26630643.
252.	Gruberg L, Hellkamp AS, Thomas LE, de Lemos JA , Scirica BM, Hilliard A, Enriquez JR, Mohsen A, Wang TY. The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry. <i>JACC Cardiovascular Inter</i> 2015; 8:1954-62. PMID: 26738665.
253.	Salahuddin UI, Pandey A, Ayers CR, See R, Neeland IJ, Gore MO, Grinsfelder DB, Abdullah SM, Khera A, de Lemos JA , McGuire DK. Effect of treatment with rosiglitazone on highsensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. <i>Diab Vasc Dis Res</i> . 2016; 1:575-83. PMID: 26701964.
254.	Khalili H, Singh R, Wood M, Edwards A, Cooper M, Ayers C, Moss E, Berry JD, Vongpatanasin W, de Lemos JA , Das SR. Premature Clopidogrel Discontinuation After DrugEluting Stent Placement in a Large Urban Safety-Net Hospital. <i>Am J Cardiol</i> . 2016;117:522-5. PMID: 26721655.
255.	Velasco A, Ayers C, Das SR, de Lemos JA , Khera A, Victor RG, Kaplan NM, Vongpatanasin W Target organ complications and prognostic significance of alerting reaction: analysis from the Dallas heart study. <i>J Hypertens</i> . 2016; 34:226-34. PMID: 26485459.
256.	Wang TY, Vora AN, Peng SA, Fonarow GC, Das S, de Lemos JA , Peterson ED. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. <i>J Am Heart Assoc</i> . 2016; 5(1). pii: e002612. PMID: 26796254.
257.	Witberg G, Ayers CR, Turer AT, Lev E, Kornowski R, de Lemos JA , Neeland IJ. Relation of Adiponectin to All-Cause Mortality, Cardiovascular Mortality, and Major Adverse Cardiovascular Events (from the Dallas Heart Study). <i>Am J Cardiol</i> . 2016;117:574-9. PMID: 26800774
258.	Vora AN, Peterson ED, Hellkamp AS, Sutton NR, Panacek E, Thomas L, de Lemos JA , Wang TY. Care Transitions After Acute Myocardial Infarction for Transferred-In Versus DirectArrival Patients. <i>Circ Cardiovasc Qual Outcomes</i> . 2016;9:109-16. PMID: 26812934.

259.	Dasari TW, Hamilton S, Chen AY, Wang TY, Peterson ED, de Lemos JA , Saucedo JF. Noneligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). <i>Am Heart J.</i> 2016;172:1-8. PMID: 26856209
260.	Shah RU, de Lemos JA , Wang TY, Chen AY, Thomas L, Sutton NR, Fang JC, Scirica BM, Henry TD, Granger CB. Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock: Findings From the NCDR. <i>J Am Coll Cardiol.</i> 2016 6:739-47 PMID: 26892407
261.	Kulinski JP, Kozlitina J, Berry JD, de Lemos JA , Khera A. Association Between Sedentary Time and Coronary Artery Calcium. <i>JACC Cardiovasc Imaging.</i> 2016; 9:1470-2. PMID: 27085428
262.	Pandey A, McGuire DK, de Lemos JA , Das SR, Berry JD, Brilakis ES, Banerjee S, Marso SP, Barsness GW, Simon DN, Roe M, Goyal A, Kosiborod M, Amsterdam EA, Kumbhani DJ. Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG). <i>Circ Cardiovasc Qual Outcomes.</i> 2016; 9:197-205. PMID: 27166210
263.	Brownell NK, Khera A, de Lemos JA , Ayers CR, Rohatgi A. Association Between Peptidoglycan Recognition Protein-1 and Incident Atherosclerotic Cardiovascular Disease Events: The Dallas Heart Study. <i>J Am Coll Cardiol.</i> 2016; 17:67 PMID: 27173041
264.	Mathews R, Fonarow GC, Li S, Peterson ED, Rumsfeld JS, Heidenreich PA, Roe MT, Oetgen WJ, Jollis JG, Cannon CP, de Lemos JA , Wang TY; National Cardiovascular Data Registry. Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. <i>Am Heart J.</i> 2016;175:1-8. PMID: 27179718
265.	Pandey A, Park BD, Ayers C, Das SR, Lakoski S, Matulevicius S, de Lemos JA , Berry JD. Determinants of Racial/Ethnic Differences in Cardiorespiratory Fitness (from the Dallas Heart Study). <i>Am J Cardiol.</i> 2016;118:499-503 PMID: 27349903
266.	Yano Y, Vongpatanasin W, Ayers C, Turer A, Chandra A, Carnethon MR, Greenland P, de Lemos JA , Neeland IJ. Regional Fat Distribution and Blood Pressure Level and Variability: The Dallas Heart Study. <i>Hypertension.</i> 2016; 68:576-83. PMID: 27432862
267.	Pandey A, Salahuddin U, Garg S, Ayers C, Kulinski J, Anand V, Mayo H, Kumbhani DJ, de Lemos J , Berry JD. Continuous Dose-Response Association Between Sedentary Time and Risk for Cardiovascular Disease: A Meta-analysis. <i>JAMA Cardiol.</i> 2016; 1:575-83. PMID: 27434872
268.	Peri-Okonny PA, Ayers C, Maalouf N, Das SR, de Lemos JA , Berry JD, Turer AT, Neeland IJ, Scherer PE, Vongpatanasin W. Adiponectin protects against incident hypertension independent of body fat distribution: observations from the Dallas Heart Study. <i>Diabetes Metab Res Rev.</i> 2016 Jul 25. [Epub ahead of print] PMID: 27455039
269.	Sutton NR, Li S, Thomas L, Wang TY, de Lemos JA , Enriquez JR, Shah RU, Fonarow GC. The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. <i>Am Heart J.</i> 2016;178:65-73 PMID: 27502853

270.	Harrison RW, Simon D, Miller AL, de Lemos JA , Peterson ED, Wang TY. Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. <i>Am Heart J.</i> 2016;178:95-101 PMID: 27502856
271.	Wayangankar SA, Roe MT, Chen AY, Gupta RS, Giugliano RP, Newby LK, de Lemos JA , Alexander KP, Sanborn TA, Saucedo JF. Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. <i>Indian Heart J.</i> 2016;68:464-72. PMID: 27543467
272.	deFilippi CR, de Lemos JA , Newman AB, Guralnik JM, Christenson RH, Pahor M, Church T, Espeland M, Krithevsy SB, Stafford R, Seliger SL; LIFE Study Group. Impact of moderate physical activity on the longitudinal trajectory of a cardiac specific biomarker of injury: Results from a randomized pilot study of exercise intervention. <i>Am Heart J.</i> 2016;179:151-6. PMID: 27595690
273.	Natriuretic Peptides Studies Collaboration (NPSC). Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes Endocrinol.</i> 2016; 4:840-9. PMID: 27599814
274.	Pandey A, Golwala H, Sheng S, DeVore AD, Hernandez AF, Bhatt DL, Heidenreich PA, Yancy CW, de Lemos JA , Fonarow GC. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. <i>JAMA Cardiol.</i> 2016;4:935-46. PMID: 28030747
275.	Masoudi FA, Ponirakis A, de Lemos JA , Jollis JG, Kremers M, Messenger JC, Moore JW, Moussa I, Oetgen WJ, Varosy PD, Vincent RN, Wei J, Curtis JP, Roe MT, Spertus JA. Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. <i>J Am Coll Cardiol.</i> 2016 Dec 20. [Epub ahead of print] PMID: 28025066
276.	Blazing MA, Giugliano RP, de Lemos JA , Cannon CP, Tonkin A, Ballantyne CM, Lewis BS, Musliner TA, Tereshakovec AM, Lokhnygina Y, White JA, Reist C, McCagg A, Braunwald E. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>Am Heart J.</i> 2016; 182:89-96. PMID: 27914504
277.	DeFina LF, Willis BL, Radford NB, Christenson RH, deFilippi CR, de Lemos JA . Cardiorespiratory Fitness and Highly Sensitive Cardiac Troponin Levels in a Preventive Medicine Cohort. <i>J Am Heart Assoc.</i> 2016; 5: pii: e003781. PMID: 27895045
278.	Lyngbakken MN, Skranes JB, de Lemos JA , Nygård S, Dalen H, Hveem K, Røsjø H, Omland T. Impact of Smoking on Circulating Cardiac Troponin I Concentrations and Cardiovascular Events in the General Population: The HUNT Study (Nord-Trøndelag Health Study). <i>Circulation.</i> 2016;134:1962-1972.PMID: 27815376
279.	Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA , Al-Khatib SM, Velazquez EJ, Peterson ED, Wang TY. Reassessment of Cardiac Function and Implantable
	Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation.</i> 2017;135:38-47 PMID: 27881561
280.	Fanaroff AC, Peterson ED, Chen AY, Thomas L, Doll JA, Fordyce CB, Newby LK, Amsterdam EA, Kosiborod MN, de Lemos JA , Wang TY. Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiol.</i> 2017; 2:36-44. PMID: 27806171

281.	Pandey A, Golwala H, Sheng S, DeVore AD, Hernandez AF, Bhatt DL, Heidenreich PA, Yancy CW, de Lemos JA , Fonarow GC. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. <i>JAMA Cardiol</i> 2017; 2:136-145. PMID: 28030747
282.	Oliver W, Matthews G, Ayers CR, Garg S, Gupta S, Neeland IJ, Drazner MH, Berry JD, Matulevicius S, de Lemos JA . Factors Associated With Left Atrial Remodeling in the General Population. <i>Circ Cardiovasc Imaging</i> . 2017;10. pii: e005047. PMID: 28153949
283.	Lew J, Sanghavi M, Ayers CR, McGuire DK, Omland T, Atzler D, Gore MO, Neeland I, Berry JD, Khera A, Rohatgi A, de Lemos JA . Sex-Based Differences in Cardiometabolic Biomarkers. <i>Circulation</i> . 2017; 5:544-555. doi: 10.1161/CIRCULATIONAHA.116.023005. PMID: 28153991.
284.	Seliger SL, Hong SN, Christenson RH, Kronmal R, Daniels LB, Lima JAC, de Lemos JA , Bertoni A, deFilippi CR. High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis). <i>Circulation</i> . 2017; 135:1494-1505. PMID: 28159799
285.	Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, Allen NB, de Lemos JA , Carnethon M, Greenland P, Berry JD. Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. <i>J Am Coll Cardiol</i> . 2017; 69:1129-1142. PMID: 28254175
286.	Pandey A, Allen NB, Ayers C, Reis JP, Moreira HT, Sidney S, Rana JS, Jacobs DR Jr, Chow LS, de Lemos JA , Carnethon M, Berry JD. Fitness in Young Adulthood and Long-Term Cardiac Structure and Function: The CARDIA Study. <i>JACC Heart Fail</i> . 2017;5:347-355. PMID: 28285119
287.	Leger KJ, Leonard D, Nielson D, de Lemos JA , Mammen PP, Winick NJ. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy. <i>J Am Heart Assoc</i> . 2017;6:. pii: e004653. PMID: 28377429.
288.	de Lemos JA , Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, Drazner MH, Budoff MJ, Greenland P, Ballantyne CM, Khera A. A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts. <i>Circulation</i> . 2017; 135:2119-32. PMID: 28360032
289.	Pandey A, Golwala H, Hall HM, Wang TY, Lu D, Xian Y, Chiswell K, Joynt KE, Goyal A, Das SR, Kumbhani D, Julien H, Fonarow GC, de Lemos JA . Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. <i>JAMA Cardiol</i> . 2017 ; 2:723-731.PMID: 28445559
290.	Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA , Witztum JL, Tsimikas. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. <i>Arterioscler Thromb Vasc Biol</i> . 2017;37:1213-21. PMID: 28473443
291.	Gregg LP, Adams-Huet B, Li X, Colbert G, Jain N, de Lemos JA , Hedayati SS. Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes. <i>J Am Heart Assoc</i> . 2017 Jul 5;6(7). PMID: 28679558

292.	Wilner B, Garg S, Ayers CR, Maroules CD, McColl R, Matulevicius SA, de Lemos JA , Drazner MH, Peshock R, Neeland IJ. Dynamic Relation of Changes in Weight and Indices of Fat Distribution With Cardiac Structure and Function: The Dallas Heart Study. <i>J Am Heart Assoc.</i> 2017 Jul 19;6(7). PMID: 28724650
293.	Neeland IJ, Das SR, Simon DN, Diercks DB, Alexander KP, Wang TY, de Lemos JA . The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR. <i>Eur Heart J Qual Care Clin Outcomes.</i> 2017;:183-191. PMID: 28838094
294.	Garg S, de Lemos JA , Matulevicius SA, Ayers C, Pandey A, Neeland IJ, Berry JD, McColl R, Maroules C, Peshock RM, Drazner MH. Association of Concentric Left Ventricular Hypertrophy With Subsequent Change in Left Ventricular End-Diastolic Volume: The Dallas Heart Study. <i>Circ Heart Fail.</i> 2017. pii: e003959. PMID: 28775115
295.	Pi Y, Roe MT, Holmes DN, Chiswell K, Garvey JL, Fonarow GC, de Lemos JA , Garratt KN, Xian Y. Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. <i>Circ Cardiovasc Qual Outcomes.</i> 2017 pii: e003490. PMID: 28794118
296.	Ren HY, Khera A, de Lemos JA , Ayers CR, Rohatgi A. Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population. <i>Am Heart J.</i> 2017;191:55-61. PMID: 28888270
297.	Paixao ARM, Neeland IJ, Ayers CR, Xing F, Berry JD, de Lemos JA , Abbara S, Peshock RM, Khera A. Defining coronary artery calcium concordance and repeatability - Implications for development and change: The Dallas Heart Study. <i>J Cardiovasc Comput Tomogr.</i> 2017; 11:347353. PMID: 28732689
298.	Harrington JL, Ayers C, Berry JD, Omland T, Pandey A, Seliger SL, Ballantyne CM, Kulinski J, deFilippi CR, de Lemos JA . Sedentary Behavior and Subclinical Cardiac Injury: Results From the Dallas Heart Study. <i>Circulation.</i> 2017;136:1451-1453 PMID: 28993375
299.	Dharmarajan K, McNamara RL, Wang Y, Masoudi FA, Ross JS, Spatz EE, Desai NR, de Lemos JA , Fonarow GC, Heidenreich PA, Bhatt DL, Bernheim SM, Slattery LE, Khan YM, Curtis JP. Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. <i>Ann Intern Med.</i> 2017;167:555-564. PMID: 28973634
300.	Khera R, Jain S, Pandey A, Agusala V, Kumbhani DJ, Das SR, Berry JD, de Lemos JA , Girotra S. Comparison of Readmission Rates After Acute Myocardial Infarction in 3 Patient Age Groups (18 to 44, 45 to 64, and ≥ 65 Years) in the United States. <i>Am J Cardiol.</i> 2017; 120:1761-1767. PMID: 28865892
301.	Gentry JL 3rd, Carruthers D, Joshi PH, Maroules CD, Ayers CR, de Lemos JA , Aagaard P, Hachamovitch R, Desai MY, Roselli EE, Dunn RE, Alexander K, Lincoln AE, Tucker AM, Phelan DM. Ascending Aortic Dimensions in Former National Football League Athletes. <i>Circ Cardiovasc Imaging.</i> 2017;11:. pii: e006852. PMID: 29122845
302.	Khera R, Pandey A, Koshy T, Ayers C, Nallamothu BK, Das SR, Drazner MH, Jessen ME, Kirtane AJ, Gardner TJ, de Lemos JA , Bhatt DL, Kumbhani DJ. Role of Hospital Volumes in Identifying Low-Performing and High-Performing Aortic and Mitral Valve Surgical Centers in the United States. <i>JAMA Cardiol.</i> 2017;2:1322-1331. PMID: 29117319

303.	Khera R, Pandey A, Ayers CR, Agusala V, Pruitt SL, Halm EA, Drazner MH, Das SR, de Lemos JA , Berry JD. Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings. <i>Circ Heart Fail</i> . 2017;11: pii: e004402. PMID: 29129828
304.	Khera R, Hong JC, Saxena A, Arrieta A, Virani SS, Blankstein R, de Lemos JA , Krumholz HM, Nasir K. Burden of Catastrophic Health Expenditures for Acute Myocardial Infarction and Stroke Among Uninsured in the United States. <i>Circulation</i> . 2018 (online before print). PMID: 29133601
305.	Mody P, Wang T, McNamara R, Das S, Li S, Chiswell K, Tsai T, Kumbhani D, Wiviott S, Goyal A, Roe M, de Lemos JA . Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. <i>Eur Heart J Qual Care Clin Outcomes</i> . 2018;4:43-50. PMID: 29293980
306.	Peters MN, Seliger SL, Christenson RH, Hong-Zohlman SN, Daniels LB, Lima JAC, de Lemos JA , Neeland IJ, deFilippi CR. "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA. <i>J Am Heart Assoc</i> . 2018 ;7. pii: e006619. PMID: 29437599
307.	Pandey A, Patel KV, Liang L, DeVore AD, Matsouaka R, Bhatt DL, Yancy CW, Hernandez AF, Heidenreich PA, de Lemos JA , Fonarow GC. Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry. <i>JAMA Cardiol</i> . 2018 Mar 12. doi: 10.1001 PMID: 29532056
308.	Saeed A, Nambi V, Sun W, Virani SS, Taffet G, Deswal A, Selvin E, Matsushita K, Wagenknecht LE, Hoogeveen R, Coresh J, de Lemos JA , Ballantyne CM. Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>J Am Coll Cardiol</i> . 2018; 71:25272536 PMID: 29535064
309.	Fanaroff AC, Chen AY, Thomas LE, Pieper KS, Garratt KN, Peterson ED, Newby LK, de Lemos JA , Kosiborod MN, Amsterdam EA, Wang TY. Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non-ST-Segment-Elevation Myocardial Infarction. <i>J Am Heart Assoc</i> . 2018;7: pii: e008894 PMID: 29802146
310.	Udell JA, Desai NR, Li S, Thomas L, de Lemos JA , Wright-Slaughter P, Zhang W, Roe MT, Bhatt DL. Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circ Cardiovasc Qual Outcomes</i> . 2018 Jun;11(6):e004054. PMID: 29848476
311.	Gregg LP, Tio MC, Li X, Adams-Huet B, de Lemos JA , Hedayati SS. Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease. <i>Am J Nephrol</i> . 2018;47:395-405. PMID: 29874658
312.	Khera R, Valero-Elizondo J, Okunrintemi V, Saxena A, Das SR, de Lemos JA , Krumholz HM, Nasir K. Association of Out-of-Pocket Annual Health Expenditures With Financial Hardship in Low-Income Adults With Atherosclerotic Cardiovascular Disease in the United States. <i>JAMA Cardiol</i> 2018;3:729-738
313.	Claudel SE, Adu-Brimpong J, Banks A, Ayers C, Albert MA, Das SR, de Lemos JA , Leonard T, Neeland IJ, Rivers JP, Powell-Wiley TM. Association between neighborhood-level socioeconomic deprivation and incident hypertension: A longitudinal analysis of data from the Dallas heart study. <i>Am Heart J</i> 2018; 204:109-118.
314.	Stamatelopoulos K, Pol CJ, Ayers C, Georgiopoulos G, Gatsiou A, Brilakis ES, Khera A, Drosatos K, de Lemos JA , Stellos K. Amyloid-Beta (1-40) Peptide and Subclinical Cardiovascular Disease. <i>J Am Coll Cardiol</i> 2018;72:1060-1061.

315.	Khera A, Budoff MJ, O'Donnell CJ, Ayers CA, Locke J, de Lemos JA , Massaro JM, McClelland RL, Taylor A, Levine BD. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator. <i>Circulation</i> 2018;138:1819-1827.
316.	Vigen R, Kutscher P, Fernandez F, Yu A, Bertulfo B, Hashim IA, Molberg K, Diercks DB, Metzger JC, Soto J, Alzubaidy D, Thibodeaux L, Joglar JA, de Lemos JA , Das SR. Evaluation of a Novel Rule-Out Myocardial Infarction Protocol Incorporating High-Sensitivity Troponin T in a US Hospital. <i>Circulation</i> 2018;138:2061-2063.
317.	Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, de Lemos JA . Antinuclear antibodies in the general population: positive association with inflammatory and vascular biomarkers but not traditional cardiovascular risk factors. <i>Clin Exp Rheumatol</i> 2018; 36:1031-7.
318.	Vongpatanasin W, Ayers C, Lodhi H, Das SR, Berry JD, Khera A, Victor RG, Lin FC, Viera AJ, Yano Y, de Lemos JA . Diagnostic Thresholds for Blood Pressure Measured at Home in the Context of the 2017 Hypertension Guideline. <i>Hypertension</i> 2018;72:1312-1319.
319.	Bhatt AB, Cheeran DD, Shemisa K, Roy L, Manz BN, Vigen R, de Lemos JA , Das SR. Physician-Specific Practice Patterns About Discharge Readiness and Heart Failure Utilization Outcomes. <i>Circ Cardiovasc Qual Outcomes</i> 2018; 11:e004365
320.	Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BL, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM, Berry JD, Khera A. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> 2018;138:2315-2325.
321.	Mody P, Brown SP, Kudenchuk PJ, Chan PS, Khera R, Ayers C, Pandey A, Kern K, de Lemos JA , Link MS, Idris AH. Intraosseous versus Intravenous access in Patients with Out-of-Hospital Cardiac Arrest: Insights from the Resuscitation Outcomes Consortium Continuous Chest Compression Trial. <i>Resuscitation</i> . 2019; 134:69-75.
322.	Kontos MC, Fordyce CB, Chen AY, Chiswell K, Enriquez JR, de Lemos J , Roe MT. Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry. <i>Clin Cardiol</i> . 2019; 42:352357.
323.	Pandey A, Keshvani N, Ayers C, Correa A, Drazner MH, Lewis A, Rodriguez CJ, Hall ME, Fox ER, Mentz RJ, deFilippi C, Seliger SL, Ballantyne CM, Neeland IJ, de Lemos JA , Berry JD. Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. <i>JAMA Cardiol</i> 2019;4:51-58.
324.	Rao S, Pandey A, Garg S, Park B, Mayo H, Després JP, Kumbhani D, de Lemos JA , Neeland IJ. Effect of Exercise and Pharmacological Interventions on Visceral Adiposity: A Systematic Review and Meta-analysis of Long-term Randomized Controlled Trials. <i>Mayo Clin Proc</i> . 2019; 94:211-224.
325.	Sulistio MS, Khera A, Squiers K, Sanghavi M, Ayers CR, Weng W, Kazi S, de Lemos JA , Johnson DH, Kirk L. Effects of gender in resident evaluations and certifying examination pass rates. <i>BMC Med Educ</i> . 2019;19:10.
326.	Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet</i> . 2019; 393:407-415.
327.	Frame IJ, Joshi PH, Mwangi C, Gunsolus I, de Lemos JA , Das SR, Sarode R, Balani J, Apple FS, Muthukumar A. Susceptibility of Cardiac Troponin Assays to Biotin Interference. <i>Am J Clin Pathol</i> . 2019; 151:486-493.

328.	Desai NR, Udell JA, Wang Y, Spatz ES, Dharmarajan K, Ahmad T, Julien HM, Annapureddy A, Goyal A, de Lemos JA , Masoudi FA, Bhatt DL, Minges KE, Krumholz HM, Curtis JP. Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. <i>Circ Cardiovasc Qual Outcomes</i> 2019;12:e004983.
329.	McNamara DA, Bennett AJ, Ayers C, de Lemos JA , Berry JD, Link MS. Early Repolarization Pattern Is Associated With Increased Left Ventricular Mass: Insights From the Dallas Heart Study. <i>JACC Clin Electrophysiol.</i> 2019; 5:395-397.
330.	Eades MT, Paixao ARM, Mehta A, Ayers CR, Joshi PH, Berry JD, de Lemos JA , Khera A. Characterization and Trajectory of Coronary Artery Calcium Percentiles: The Dallas Heart Study. <i>JACC Cardiovasc Imaging.</i> 2019 epub ahead of print
331.	Hashim IA, Vigen R, Fernandez F, Yu A, Bertulfo B, Thibodeaux L, Das SR, Diercks D, de Lemos JA , Kutscher P. Validation and implementation of the fifth-generation high sensitivity Troponin T (hs-TnT) assay at a large teaching county hospital. A laboratory-driven multispecialty effort. <i>Clin Chim Acta.</i> 2019; 495:85-87.
332.	Shavadia JS, Chen AY, Fanaroff AC, de Lemos JA , Kontos MC, Wang TY. Intensive Care Utilization in Stable Patients With ST-Segment Elevation Myocardial Infarction Treated With Rapid Reperfusion. <i>JACC Cardiovasc Interv.</i> 2019; 12:709-717.
333.	McCarthy CP, Vaduganathan M, Patel KV, Lalani HS, Ayers C, Bhatt DL, Januzzi JL Jr, de Lemos JA , Yancy C, Fonarow GC, Pandey A. Association of the New Peer Group-Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Netw Open.</i> 2019;2(4):e192987.
334.	Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA , Ballantyne CM. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. <i>Circulation.</i> 2019 (epub ahead of print)
335.	Serrano CV Jr, de Mattos FR, Pitta FG, Nomura CH, de Lemos JA , Ramires JAF, Kalil-Filho R. Association between Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study. <i>Mediators Inflamm.</i> 2019:6513847 (epub)

Reviews, Chapters, Monographs and Editorials

1.	de Lemos JA , Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. <i>J Am Soc Nephrol</i> 1996; 7:2044-54. PMID:8915964
2.	de Lemos JA , Cannon CP. Reocclusion after AMI: glycoprotein IIa/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. in <u>Thrombolytic Therapy: New Standards of Care-Part VI</u> . Excerpta Medica, Inc., 1998, pp. 3-11.
3.	de Lemos JA . ST-Segment resolution as a marker of epicardial and myocardial reperfusion after thrombolysis: Insights from the TIMI 14 and InTIME-II trials. <i>J Electrocardiography</i> 2000; 33(suppl):67-72. PMID:11265739
4.	de Lemos JA , Cannon CP. "Angina and Coronary Heart Disease." In Sirtori C., ed. <u>European Textbook of Clinical Pharmacology</u> . McGraw Hill 2000; 269-85.
5.	Antman EM, de Lemos JA , Braunwald E. Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction. <i>Eur Heart J</i> 2001; 3(suppl A):A8-A13.

6.	de Lemos JA. The effects of combined thrombolytic and platelet inhibitor therapy on myocardial and microvascular perfusion. <i>Md Med</i> 2001; Spring suppl: 88-89. PMID:11434069
7.	Watkins SP, de Lemos JA. Antiplatelet therapy in acute myocardial infarction: combining glycoprotein IIB/IIIA inhibition with reduced-dose fibrinolytic therapy. <i>Current Interventional Cardiology Reports</i> 2001; 3:235-43.
8.	de Lemos JA, Cannon CP, Stone PH. "Acute Myocardial Infarction." In Rosendorf C., ed. <i>Essential Cardiology.</i> WB Saunders 2001; 463-501.
9.	Mauri L, de Lemos JA, O'Gara PT. Infective Endocarditis. <i>Curr Probl Cardiol</i> 2001; 26:562610. PMID:11584248
10.	de Lemos JA, Braunwald E. ST segment resolution as a tool for evaluating the efficacy of reperfusion therapy. <i>J Am Coll Cardiol</i> 2001; 38:1283-94. PMID:11691496
11.	de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application?[editorial] <i>Circulation</i> 2002; 106:2868-70. PMID:12460861
12.	de Lemos JA. "Traditional and Novel Risk Factors." In Lewis, RP, ed. <u>American College of Cardiology Self Assessment Program (ACCSAP), 5th Edition.</u> American College of Cardiology 2002.
13.	de Lemos JA, McGuire DK, Drazner MH. B-type Natriuretic Peptide (BNP) in Cardiovascular Disease. <i>Lancet</i> 2003;362:316-22. PMID:12892964
14.	Le BD, Addo T, de Lemos JA. The endocrine heart: B-type natriuretic peptide as a diagnostic and therapeutic agent in cardiovascular disease. <i>The Endocrinologist</i> 2003;13:97105.
15.	Morrow DA, de Lemos JA. Assessing the Success of Fibrinolysis: Can we let the interventionalist rest?[editorial] <i>Am Heart J</i> 2003;145:380-82.
16.	Morrow DA, de Lemos JA, Sabatine MS, Antman EM. The Search for a Biomarker of Cardiac Ischemia.[editorial] <i>Clin Chem</i> 2003;49:537-39.
17.	Deo R, de Lemos JA. B-type natriuretic peptide (BNP) in ischemic heart disease. <i>Curr Cardiol Rep</i> 2003; 5:271-7. PMID:12801444
18.	de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. <i>Rev Cardiovasc Med.</i> 2003; Suppl 4:S37-46. PMID:14564227
19.	Maewal P, de Lemos JA. Natriuretic peptide hormone measurement in acute coronary syndromes. <i>Heart Fail Rev</i> 2003;4:365-8. PMID:14574059
20.	de Lemos JA. "ST Elevation Myocardial Infarction." In Irwin R and Rippe J, ed. <u>Irwin and Rippe's Intensive Care Medicine 5th edition.</u> Lippincott, William and Wilkins 2003; 400-413.
21.	de Lemos JA, Morrow DA. Noninvasive assessment of reperfusion therapy: slow progress towards a worthwhile goal.[editorial] <i>Am Heart J</i> 2003;146:747-9. PMID:14597920
22.	de Lemos JA, Warner JJ. New tools for assessing microvascular obstruction in patients with ST elevation myocardial infarction. [editorial] <i>Heart.</i> 2004;90:119-20. PMID:14729767
23.	de Lemos JA. "Acute Coronary Syndromes." In Rutherford JD, ed. <u>Cardiology Core Curriculum: A Problem-Based Approach.</u> BMJ Books 2003;174-204.
24.	Cogan J, Cannon CP, de Lemos JA. "Treatment of Unstable Angina and Non-ST Elevation Myocardial Infarction." In Llevadot J, ed. <u>Sindromes Coronarios Agudos.</u> Elsevier (Spain), 2003;229-255.
25.	Gibson CM, de Lemos JA, Antman EM. Time is muscle in primary PCI: the strength of the evidence grows. [editorial] <i>Eur Heart J</i> 2004;25:1001-2. PMID:15191768

26.	Wiviott SD, de Lemos JA , Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. <i>Clin Chem Acta</i> 2004;346:119-28.
27.	Mo V and de Lemos JA . Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. <i>Curr Cardiol Rep.</i> 2004; 6:273-8. PMID:15182604
28.	Drazner MH, de Lemos JA . Unexpected BNP Levels in Patients with Advanced Heart Failure: A Tale of Caution and Promise.[editorial] <i>Am Heart J</i> 2005; 149:187-9. PMID:15846253
29.	Aroney CN, de Lemos JA . "Management of the Acute Coronary Syndromes." In Wu A, ed. <i>Cardiac Markers, 2nd edition</i> . The Humana Press 2004. PMID:21956498
30.	Abdullah SM, de Lemos JA . Commentary to: Whitney et al. "A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effect on progression of coronary heart disease and clinical events. <i>Evidenced-Based Cardiovascular Medicine</i> 2005; 9:108-11.
31.	Keeley EC, de Lemos JA . Free wall rupture in the elderly: deleterious effect of fibrinolytic therapy on the aging heart.[editorial]. <i>Eur Heart J</i> 2005 26:1693-4. PMID:15972292
32.	Markham DW and de Lemos JA . Screening for cardiovascular disease using B-type natriuretic peptides: detecting an imbalance of the four humours. [editorial] <i>Eur Heart J</i> 2005; 26:2220-21. PMID:16123047
33.	Mo V and de Lemos JA . The use of monocyte chemoattractant protein-1 and soluble CD40 ligand in a pathophysiology-guided approach to the management of coronary artery disease. <i>Future Cardiol</i> 2005;1:649-56. PMID:19804105
34.	Parikh S and de Lemos JA . Current Therapeutic Strategies in Cardiac Amyloidosis. <i>Curr Treat Options Cardiovasc Med.</i> 2005;7:443-8. PMID:16283971
35.	Mehta S and de Lemos JA . Appropriate Invasive and Conservative Strategies for Patients with non-ST-Elevation Acute Coronary Syndromes. <i>Current Opinion Cardiol</i> 2005; 20:536-40. PMID:16234627
36.	See R and de Lemos JA . Current status of risk stratification methods in acute coronary syndromes. <i>Curr Cardiol Rep</i> 2006;8:282-8. PMID:16822363
37.	de Lemos JA . "Traditional and Novel Risk Factors." In Rutherford JD, ed. <i>Chronic Coronary Artery Disease in American College of Cardiology Self Assessment Program (ACCSAP), 6th Edition</i> . American College of Cardiology 2005.
38.	Adesanya AO, de Lemos JA , Greulich NB, Whitten CW. Management of perioperative myocardial infarction in noncardiac surgical patients. <i>Chest</i> 2006;130:584-596. PMID:16899865
39.	Deo R, Cannon CP, and de Lemos JA . "ST Elevation Myocardial Infarction." In Rosendorf C., ed. <i>Essential Cardiology 2nd Edition</i> . WB Saunders 2005.
40.	Patel C, Wynne K, de Lemos JA , McGuire DK. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR γ agonism. <i>Diabetes & Vascular Disease Research</i> 2006; 3:65-71. PMID:17058625
41.	Parikh SV and de Lemos JA . Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. <i>Am J Med Sci</i> 2006; 332:186-97. PMID:17031244
42.	de Lemos JA . The Latest and Greatest New Biomarkers: Which Ones Should We Measure for Risk Prediction in Our Practice? [editorial] <i>Arch Int Med</i> 2006;166:2428-30. PMID:17159006
43.	de Lemos JA . Cardiovascular biomarkers for acute coronary syndromes using a multi-marker strategy. <i>Emergency Medicine and Critical Care Review</i> 2006.20-22.

44.	Wallace TW and de Lemos JA . "ST-Segment Elevation Myocardial Infarction," In Irwin R and Rippe J, ed. <u>Manual of Intensive Care Medicine</u> , 4 th edition. Lippincott, Williams, & Wilkins 2006;195-201.
45.	Abdullah SM, de Lemos JA . "Natriuretic Peptides in Acute and Chronic Coronary Artery Disease." In Morrow DA ed. <u>Cardiac Biomarkers in the Management of Cardiovascular Disease</u> . The Humana Press 2006;409-426.
46.	Patel M and de Lemos JA . Can biomarkers improve prediction of future cardiovascular events in patients with cardiovascular disease? [editorial] <i>Nat Med Clin Prac</i> 2007; 4:14-15. PMID:17180141
47.	Morrow DA and de Lemos JA . Benchmarks for the assessment of novel cardiovascular biomarkers. [editorial] <i>Circulation</i> 2007; 115:949-52. PMID:17325253
48.	de Lemos JA and Morrow DA. Use of Natriuretic Peptides in Clinical Decision-making for Patients with Non-ST Elevation Acute Coronary Syndromes. [editorial] <i>Am Heart J</i> 2007 153:450-3. PMID:17383278
49.	Baber U, Toto RD, de Lemos JA . Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. <i>Am Heart J</i> . 2007; 153:471-7. PMID:17383281
50.	Link JJ, Rohatgi A, de Lemos JA . HDL Cholesterol: Physiology, Pathophysiology, and Management. <i>Curr Probl Cardiol</i> . 2007; 32:268-314. ID:17481993
51.	Gupta S and de Lemos JA . Use and misuse of cardiac troponins in clinical practice. <i>Prog Cardiovasc Dis</i> 2007;50:151-65. PMID:17765476
52.	Wiviott SD, de Lemos JA . Antiplatelet agents make a comeback in ST-elevation myocardial infarction. [editorial] <i>Am Heart J</i> 2007; 154:603-6. PMID:17892976
53.	Link JJ, Warner JJ, de Lemos JA . Low Molecular Weight Heparin Use in Acute Coronary Syndromes and Percutaneous Coronary Interventions: An Update. <i>Curr Cardio Risk Report</i> 2007;1:303-9.
54.	de Lemos JA and O'Donoghue M. The skinny on fatty acid binding protein.[editorial] <i>J Am Coll Cardiol</i> 2007; 50:2068-70. PMID:18021875
55.	de Lemos JA and Morrow DA. "ST Elevation Myocardial Infarction." In Irwin R and Rippe J, ed. <u>Irwin and Rippe's Intensive Care Medicine</u> 6 th edition. Lippincott, William and Wilkins 2007; 428-42.
56.	de Lemos JA and Hildebrandt P. Amino-terminal pro-B-type natriuretic peptides: testing in general populations. <i>Am J Cardiol</i> . 2008;101(3A):16-20. PMID:18243852
57.	Omland T and de Lemos JA . Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart disease. <i>Am J Cardiol</i> . 2008;10 (3A)1:61-6.
58.	Aghababian RV, Ballantyne CM, Berger P, Bhatt DL, Blumenthal R, Boden W, Bresler M, Califf RM, Cannon CP, Chesebro J, Cohen JD, Cohen M, de Lemos JA , Diercks D, Fonarow GC, Bigler WB, Giugliano R, Graff LG, Grines C, Hochman J, Hoekstra J, Holmes DR, Janicke D, King SB 3rd, Krumholz HM, Lakkis N, Libby P, Mahaffey K, Mehta SR, Moliterno D, Morrow D, Moses JW, Newby K, Ornato J, Peterson E, Pollack C, Popma JJ, Price M, Rapaport E, Sabatine M, Shah PK, Smith SC Jr, Steinhubl SR, Teirstein P, Willerson J, Yusuf S. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. <i>Crit Pathw Cardiol</i> 2008;7:43-81. PMID:18458666
59.	de Lemos JA and Lloyd-Jones D. Multiple Biomarker Panels for Cardiovascular Risk Assessment. [editorial] <i>N Engl J Med</i> 2008;358:2172-4. PMID:18480211

60.	Wood FO and de Lemos JA . Sorting through new biomarkers. <i>Curr Cardiol Rep</i> 2008; 10:319-26. PMID:18611367
61.	de Lemos JA , and O'Rourke RA. "Unstable Angina and Non-ST Elevation Myocardial Infarction." In Fuster V, O'Rourke RA et al, ed. <u>Hurst's the Heart, 12th edition</u> . McGraw Hill, Inc, 2008;1351-74.
62.	de Lemos JA . "NT-proBNP in General Population-Based Testing." In Bayes-Genis A, Januzzi JL, ed. <u>NT-proBNP as a Biomarker in Cardiovascular Diseases</u> . Thomson Reuters 2008; 23-34.
63.	Shah SH and de Lemos JA . Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment.[editorial] <i>JAMA</i> 2009;302:92-3. PMID:19567447
64.	Gupta S, Drazner MH, de Lemos JA . Newer Biomarkers in Heart Failure. <i>Heart Fail Clin</i> 2009; 5:79-88.
65.	Rohatgi A, de Lemos JA . The report card on growth differentiation factor 15: consistent marks but not yet ready for promotion [editorial]. <i>Circ Cardiovasc Genet</i> . 2009; 2:209-11. PMID:20031588
66.	de Lemos JA , Khera A. Keeping our eyes on the prize: low density lipoprotein cholesterol [editorial]. <i>Am J Cardiol</i> . 2009;104:1697-8. PMID:19962478
67.	Matulevicius SA, Rohatgi A, de Lemos JA . "Diagnosis and Management of Patients with Unstable Angina and Non-ST Elevation Myocardial Infarction." In O'Rourke RA, Walsh RA, Fuster V, ed. " <u>Hurst's The Heart; Manual of Cardiology, 12th ed.</u> " McGraw Hill, Inc, 2009;296314.
68.	de Lemos JA , Rohatgi A. Separating the contenders from the pretenders: competitive high throughput biomarker screening in large population-based studies [editorial]. <i>Circulation</i> 2010;121:2381-3. PMID:20497975
69.	McCullough PA, Peacock WF, O'Neil B, de Lemos JA , Lepor NE, Berkowitz R. An evidencebased algorithm for the use of B-type natriuretic testing in acute coronary syndromes. <i>Rev Cardiovasc Med</i> . 2010;11 Suppl 2:S51-65. PMID:20700103
70.	McCullough PA, Peacock WF, O'Neil B, de Lemos JA . Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. <i>Rev Cardiovasc Med</i> . 2010;11 Suppl 2:S3-12. PMID:20700100
71.	de Lemos JA , Peacock WF, McCullough PA. Natriuretic peptides in the prognosis and management of acute coronary syndromes. <i>Rev Cardiovasc Med</i> . 2010;11 Suppl 2:S24-34. PMID:20700099
72.	Enriquez JR, de Lemos JA . Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? <i>Point. Prev Cardiol</i> . 2010;13:152-9. PMID:20860637
73.	Wood FO and de Lemos JA . "ST-Segment Elevation Myocardial Infarction," In Irwin R and Rippe J, ed. <u>Manual of Intensive Care Medicine, 5th edition</u> . Lippincott, Williams, & Wilkins 2010;214-22.
74.	Patel MJ and de Lemos JA . "Hypotension" in Green H.L. ed. <u>Decision Making in Medicine, An Algorithmic Approach</u> , 3rd edition. Mosby, Inc. 2010; 76-77
75.	Nesbitt WH and de Lemos JA . "Syncope" in Green H.L. ed. <u>Decision Making in Medicine, An Algorithmic Approach</u> , 3rd edition. Mosby, Inc. 2010; 74-75.

76.	Baber U and de Lemos JA . “Hypertension” in Green H.L. ed. <u>Decision Making in Medicine, An Algorithmic Approach</u> , 3rd edition. Mosby, Inc. 2010; 80-81.
77.	de Lemos JA , Morrow DA, DeFilippi CR. Highly Sensitive Troponin Assays and the Cardiology Community: A Love/Hate Relationship? [viewpoint]. Clin Chem 2011; 57:82629. PMID:21471249
78.	de Lemos JA , McGuire DK. Biomarkers in clinical trials: can we move from fortune telling to disease profiling? [editorial]. Circulation 2011; 124:663-5. PMID:21824932
79.	Gupta N and de Lemos JA . “Emerging Biomarkers in Acute Coronary Syndromes,” in <u>Cardiac Biomarkers in Clinical Practice</u> . Jones & Bartlett Publishers 2011; 199-220.
80.	de Lemos JA , O’Rourke RA, Harrington RA. “Unstable Angina and Non-ST Elevation Myocardial Infarction.” In Fuster V, Fuster V, Walsh RA, Harrington R et al, ed. <u>Hurst’s the Heart, 13th edition</u> . McGraw Hill, Inc, 2011;1328-53.
81.	de Lemos JA and Morrow DA. “ST Elevation Myocardial infarction.” In Irwin R and Rippe J, ed. <u>Irwin and Rippe’s Intensive Care Medicine 7th edition</u> . Lippincott, William and Wilkins 2011; 402-18.
82.	de Lemos JA , Brilakis ES. No free lunches: balancing bleeding and efficacy with ticagrelor [editorial]. Eur Heart J 2011;32:2919-21. PMID:22096089
83.	de Lemos JA , Grundy SM. Low levels of circulating troponin as an intermediate phenotype in the pathway to heart failure [editorial]. J Am Coll Cardiol. 2012;59:490-2. PMID:22281252
84.	Krim SR, Vivo RP, de Lemos JA . B-type Natriuretic Peptides in Acute Coronary Syndromes: Implications in an Aging Population. Clin Cardiol. 2012; 35:682-5. PMID:22760818
85.	Neeland IJ, Kontos MC, de Lemos JA . Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. [Viewpoint]. J Am Coll Cardiol 2012; 60:96-105. PMID:22766335
86.	Neeland IJ and de Lemos JA . “ST elevation Myocardial Infarction,” in Irwin RS, Lilly C and Rippe JM, eds. <u>Manual of Intensive Care Medicine, 6th ed.</u> Lippincott, Williams and Wilkins (in press)
87.	de Lemos JA . Increasingly sensitive assays for cardiac troponins. a review. JAMA 2013; 309:2262-9. PMID:23736735
88.	de Lemos JA , deFilippi CR. Prevalence and significance of detectable troponins as measured by highly sensitive assays in the general population. Coron Artery Dis 2013; 24:705-9. PMID:24201087
89.	Hill DA, Drazner MH, de Lemos JA . Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection? Curr Opin Organ Transplant. 2013 Aug 29. [Epub ahead of print]
90.	de Lemos JA , Kumbhani DJ. Lessons from the heart: troponin elevations in patients with established peripheral artery disease [editorial]. J Am Coll Cardiol. 2014; 63:1539-41. PMID:23810876
91.	Khalili H, de Lemos JA . What constitutes a relevant change in high-sensitivity troponin values over serial measurement? [editorial] Clin Chem 2014;60:803-5. PMID:24718911
92.	Paixao AR, de Lemos JA , Khera A. Application of the new cholesterol guidelines. [letter] N Engl J Med 2014;371:78. PMID:24988565
93.	de Lemos JA , Vigen R. Keeping the genie in the bottle: growth hormone and cardiovascular disease [editorial]. J Am Coll Cardiol 2014;64:1461-3. PMID:25277617
94.	Paixao AR, de Lemos JA . Acute troponin elevation and the classification of myocardial infarction. JAMA 2014;312:2032-3. PMID:25399280

95.	de Lemos JA , Neeland IJ. Is subclinical myocardial injury the smoking gun linking obesity with heart failure? [editorial] <i>JACC Heart Fail</i> 2014; 2:608-10. PMID:25443113
96.	de Lemos JA , Neeland IJ. Separating the VAT from the FAT: new insights into the cardiometabolic risks of obesity [editorial]. <i>JACC Cardiovasc Imaging</i> 2014; 7: 1236-8. PMID:25496542
97.	Colbert g, Jain N, de Lemos JA , Hedayati SS. Utility of traditional circulating and imagingbased cardiac biomarkers in patients with predialysis CKD. <i>Clin J Am Soc Nephrol</i> 2015; 10:515-29. PMID: 25403922
98.	Lofthus DM, Gadgil JY, de Lemos JA . Overriding Concerns: The Role of Electronic Medical Record-Based Best Practice Alerts in Reducing Unnecessary Laboratory Testing. [editorial] <i>Clin Chem.</i> 2015; 61:456-8. PMID: 25595437.
99.	de Lemos JA , Rohatgi A, Ayers CR. Applying a Big Data Approach to Biomarker Discovery: Running Before We Walk?--- <i>Circulation.</i> 2015;132:2289-92. PMID: 26518764
100.	Rosendorff C; Writing Committee. Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement. <i>Am J Med.</i> 2016;129:372-8. PMID: 26655222
101.	Kumbhani DJ, de Lemos JA . Finding an effective treatment for microvascular obstruction in STEMI: a road to perdition? <i>Eur Heart J.</i> 2016;37:1920-2. PMID: 27194779
102.	Gore MO, de Lemos JA . Cardiac Troponins and the Future of Precision Medicine. <i>Circ Cardiovasc Interv.</i> 2016;9: pii: e004031. PMID: 27296203
103.	Neeland IJ, de Lemos JA . Time to Retire the BMI?: Evaluating Abdominal Adipose Tissue Imaging as Novel Cardiovascular Risk Biomarker. <i>J Am Coll Cardiol.</i> 2016; 68:1522-4. PMID: 27687193
104.	Masoudi FA, Ponirakis A, de Lemos JA , Jollis JG, Kremers M, Messenger JC, Moore JW, Moussa I, Oetgen WJ, Varosy PD, Vincent RN, Wei J, Curtis JP, Roe MT, Spertus JA. Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. <i>J Am Coll Cardiol.</i> 2017;69:1427-1450. PMID: 28025065
105.	Masoudi FA, Ponirakis A, de Lemos JA , Jollis JG, Kremers M, Messenger JC, Moore JW, Moussa I, Oetgen WJ, Varosy PD, Vincent RN, Wei J, Curtis JP, Roe MT, Spertus JA. Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. <i>J Am Coll Cardiol.</i> 2017; 69:1424-1426. PMID: 28025066
106.	Hill JA, de Lemos JA , McGuire DK; Circulation Editors Team. Recognized Outstanding Reviewers for Circulation in 2017. <i>Circulation.</i> 2017;1:2399. PMID: 29255119
107.	Patel KV, Pandey A, de Lemos JA . A Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. <i>Circulation</i> 2018; 137:2551-3. PMID: 29643058
108.	de Lemos JA . Technology Meets Opportunity: High-Sensitivity Troponin Testing for Screening Apparently Healthy Adults. <i>Clin Chem.</i> 2019; 65:593-4.
109.	de Lemos JA , Das SR. Closing the Book on Androgens and Natriuretic Peptides. <i>J Am Coll Cardiol</i> 2019; 73:1297-1299

Books/Textbooks

1.	de Lemos JA (section editor for section 7 “Other Cardiovascular Conditions”) in Antman EM, ed. <u>Cardiovascular Therapeutics: A companion to Braunwald’s Heart Disease</u> , 3 rd ed., Saunders, 2007.
2.	de Lemos JA (ed). <u>Biomarkers in Heart Disease</u> . Blackwell Publishing, 2008.
3.	de Lemos JA (section editor for section 10, “Acute Myocardial Infarction) in O’Gara PT, Hirsch GA, Fang JC, ed, <u>American College of Cardiology Self Assessment Program (ACCSAP)</u> , 7 th Edition. American College of Cardiology 2009.
4.	Scirica BM, Cannon CP, de Lemos JA , ed. <u>Focus on Acute Coronary Syndromes, version 2. (ACC F Self Assessment Program)</u> . American College of Cardiology 2010.
5.	de Lemos JA (section editor for section 7 “Other Cardiovascular Conditions”) in Antman EM, ed. <u>Cardiovascular Therapeutics: A companion to Braunwald’s Heart Disease</u> , 4 th ed., Saunders, 2013.

Case Reports

1.	de Lemos JA , Delacretaz E, Piana RN, Smith T, Rivero J, Simon DI, Friedman PL. Ebstein’s Anomaly associated with an anomalous coronary artery, two myocardial bridges, and a Mahaim fiber. <i>Circulation</i> 1999; 100:1757-59.
2.	Mehta SK, Cogan J, Reimold S, de Lemos JA . Primary Systemic Amyloidosis Presenting with Advanced Heart Failure. <i>Cardiol Rev</i> 2002;11:152-5.
3.	Le BD, Waite M, de Lemos JA , Peterson G. Left Hemiparesis From Atrial Myxoma Emboli. <i>Cardiol Rev</i> 2003; 11:41-43.
4.	Rogers N, Nguyen N, Minniefield NE, Jessen ME, de Lemos JA . Fracture and Embolization of an Inferior Vena Cava Filter Strut Leading to Cardiac Tamponade. <i>Circulation</i> 2009;119(18):2535-6.

Letters to the Editor

1.	de Lemos JA , Morrow DA, Braunwald E. B-type Natriuretic Peptide and Acute Coronary Syndromes. [response]. <i>N Eng J Med</i> 2002;346:453-3.
2.	Drazner M, McGuire DK, de Lemos JA . Nesiritide in Acute Heart Failure.[response] <i>Lancet</i> 2003;362:988-99.
3.	de Lemos JA , McGuire DK. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. <i>N Engl J Med</i> 2003;348:560-63
4.	de Lemos JA , Blazing MA, Califf RM, Wiviott SD, Braunwald E. High Dose Statins in Acute Coronary Syndromes. [response]. <i>JAMA</i> 2005;293:38-9.
5.	de Lemos JA , Christenson RH and deFilippi CR. Highly sensitive cardiac troponin T assay, cardiac disease, and mortality risk.[response]. <i>JAMA</i> 2011; 305:1196-97.
6.	Das Sr, de Lemos JA . Severe obesity and ST elevation myocardial infarction: the evolving challenge. [response]. <i>J Am Coll Cardiol</i> 2012; 59;1732.
7.	Neeland IJ, de Lemos JA . Rates of cardiac catheterization cancellation for ST elevation myocardial infarction after activation by emergency medical services or emergency physicians; results from the North Carolina Catheterization Laboratory Activation Registry. <i>Circulation</i> 2012; 126:e135.
8.	Neeland IJ, Turer AT, de Lemos JA . Measures of adiposity and fat distribution and risk of diabetes—reply. [response]. <i>JAMA</i> 2013;309:340.
9.	de Lemos JA . Assays for cardiac troponins—reply.[response] <i>JAMA</i> 2013;p310:1503-4.

10.	Brayton KM, Patel VG, Stave C, de Lemos JA , Kumbhani DJ. Reply—safety of same-day discharge after percutaneous coronary intervention: what is the level of evidence? <i>J Am Coll Cardiol</i> 2014; 63:492.
11.	Paixao AR, de Lemos JA , Khera A. Application of the new cholesterol guidelines. <i>N Engl J Med</i> 2014;371:78

Proceedings of Meetings

None

Clinical Practice Guidelines and Scientific Statements

1.	McCord J, Jneid H, Hollander JE, de Lemos JA , Cercek B, Hsue P, Gibler WB, Ohman EM, Drew B, Philippides G, Newby LK. Management of Cocaine-Associated Chest Pain and Myocardial Infarction. A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. <i>Circulation</i> 2008; 17:1897-1907.
2.	Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. <i>Eur Heart J</i> . 2012;33:2551-2567. Also published in <i>JACC</i> 2012;60:1581-98. [Recognized document reviewer]
3.	O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA , Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i> . 2012 Dec 12. doi:pii: S0735-1097(12)05562-3. Also published in <i>Circulation</i> . 2012 Dec 17.
4.	O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA , Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i> . 2012 Dec 13. doi:pii: S0735-1097(12)05561-1. Also published in <i>Circulation</i> . 2012 Dec 17.
5.	Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA , Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Circulation</i> . 2015;131:e435-70. PMID: 25829340 Also published in <i>JACC</i> (PMID 25840655), <i>Hypertension</i> (PMID 25828847) and <i>J Am Soc Hypertens</i> (PMID 25840695)
6.	Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID,

	Mukherjee D, Ting HH, O'Gara PT, Kushner FG, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA , Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i> . 2015 Oct 21. pii: CIR.0000000000000336. PMID: 26490017. Also published in <i>JACC</i> (PMID 26498666)
7.	Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). <i>Eur Heart J</i> . 2019; 40:237-69. Also published in <i>JACC</i> and <i>Circulation</i> .

Non-peer reviewed scientific or medical publications/materials in print or other media

1.	de Lemos JA , Cannon, CP. "Improving Reperfusion in Acute Myocardial Infarction: Glycoprotein IIb/IIIa Receptor Inhibitors and Percutaneous Revascularization as Adjuncts to Thrombolytic Therapy." In: Cannon, CP, ed. <i>Chest Pain Online</i> , 2000 (www.chestpainonline.org)
2.	de Lemos JA . "Emerging Role of <i>Chlamydia Pneumonia</i> in Inflammation and Coronary Artery Disease." In: Cannon, CP, ed. <i>Chest Pain Online</i> , 2000 (www.chestpainonline.org)
3.	de Lemos JA , Gersh B. "Beyond TIMI 3 Flow: from arterial to myocardial perfusion." Recorded ACCEL Interview, February 2002.
4.	de Lemos JA , Fye B. "BNP and other cardiac markers in ACS." Recorded ACCEL Interview, March 2004.
5.	de Lemos JA , Fuster V. "Novel Cardiac Biomarkers in ACS." Recorded ACCEL Interview, Sept 2005.
6.	de Lemos JA , Peacock F, Ohman M, and Hutter D. "Biomarkers." <u>ACC Conversations with Experts</u> . Nov 2005.
7.	Rohatgi A and de Lemos JA . "Novel cardiac biomarkers for ACS without ST elevation." Braunwald E ed. <u>Harrison's Online</u> , 16 th ed. 2005. (Online date 12/30/05).
8.	de Lemos JA . Multiple Biomarker Strategies in Coronary Artery Disease [transcript]. <i>Cardiosource</i> Web Site, American College of Cardiology Foundation. Available at http://www.cardiosource.com/expertopinions/programHlts/interviewDetail.asp?interviewID=325 . Accessed July 5, 2007. Published in <i>J Am Coll Cardiol</i> 7/3/07; CS2-CS8.
9.	de Lemos JA . Role of the Cardiologist in the Management of the Morbidly Obese Patient [transcript]. <i>Cardiosource</i> Web Site, American College of Cardiology Foundation. http://www.cardiosource.com/expertopinions/programHlts/interviewDetail.asp?interviewID=347 . Accessed June 10, 2008.
10	de Lemos JA , Kuvin JT. The ACS Continuum: Current and Emerging Management Strategies. American Heart Association Webcast. www.learn.heart.org .
11	de Lemos JA , Khera A Biomarkers and Genetics for Detection of Preclinical Cardiovascular Disease. In: Zipes DP, Libby P, Bonow RO, Braunwald EB, eds. <i>Braunwald's Heart Disease</i> , Online supplement, 2009.

12	Giugliano RP, Blazing MA, de Lemos JA , Braun LT. Managing Lipids in High Risk Patient Populations. A Cardiosource Virtual Learning Initiative. www.cardiosource.com/lipids .
13	de Lemos JA . Implications of highly sensitive troponin assays. Cardiosource Web Site, American College of Cardiology Foundation 2011.
14	Roberts WC, de Lemos JA , Libby P. Which is more important: plaque quantity or plaque rupture? Med Roundtable Cardiovasc Ed 2011; 2:41-7.
15	Neeland IJ, de Lemos JA . "Elevated cardiac troponin identifies a malignant phenotype of left ventricular hypertrophy." Recorded ACCEL Interview, Dec 2013.
16	Thompson PD, de Lemos JA , Lavie C, Kiernan F. Secondary prevention after acute coronary syndromes. Med Roundtable Cardiovasc Ed 2014; 3:251-61.
17	Mody P, de Lemos JA . Will the Use of High-Sensitivity Troponin Increase the Frequency of Diagnosis of MI? http://www.acc.org . June 20, 2016. http://www.acc.org/latest-incardiology/articles/2016/06/20/07/30/will-the-use-of-high-sensitivity-troponin-increase-the-frequency-of-diagnosis-of-mi
18	Wilner B, de Lemos JA , Neeland IJ. LBBB in Patients With Suspected MI: An Evolving Paradigm. http://www.acc.org . Feb. 28, 2017. http://www.acc.org/latest-incardiology/articles/2017/02/28/14/10/lbbb-in-patients-with-suspected-mi .